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Abstract 
 
In external photon beam radiotherapy, patient-related errors are common to occur during the 
treatment course of the patient. These errors, such as tumor regression or tumor shift, may result in 
discrepancies between the planned and the actually delivered dose distribution to the patient. In 
this way, it is vital to perform dose verification during the treatment course of the patient to detect 
these errors and ensure treatment quality. The Electronic Portal Imaging Device (EPID) has been 
used as a tool for performing both pre-treatment and in-treatment dose verification. Since the 
introduction of more complex beam delivering techniques, especially Volumetric Modulated Arc 
Therapy (VMAT), more complex dose verification methods based in EPID dosimetry have also been 
introduced such as 2D time-integrated portal dosimetry, 3D time-integrated portal dosimetry and, 
more recently, 2D time-resolved portal dosimetry.  
The main goal of this project was to compare the performance of 2D time-integrated, 3D time-
integrated and 2D time-resolved portal dosimetry in detecting dose discrepancies caused by 
simulated errors related to the patient’s anatomy.  
Multiple tumor shifts, tumor regressions and pleural effusion (excess fluid that accumulates in the 
pleural cavity) levels inside the lung were simulated in the planning CT-scan of six lung cancer 
patients treated with VMAT at MAASTRO clinic. Portal dose images were calculated in the original 
and manipulated planning-CT scans with the three portal dosimetry methods. For dose comparison 
2D time-integrated, 2D-time resolved and 3D time-integrated gamma analyses were performed for 
each geometrical change and each patient employing five different gamma criteria. As main results, 
3D time-integrated portal dosimetry demonstrated the highest performance (AUC = 0.85) in 
detecting tumor shifts and 2D time-resolved portal dosimetry revealed the highest performance in 
detecting tumor regressions (AUC = 0.93) and pleural effusion. A correlation between D95% changes 
in the DVHs and gamma fail rates was found at individual patient level but not at the patient cohort 
level.  
A phantom experiment was done to replicate the tumor shifts simulated in the patients. A set of 
simulations and measurements were performed following the same protocol. The dynamic thorax 
phantom was irradiated with VMAT for each tumor shift applied.  The dose to the tumor was 
determined with film dosimetry and EPID images were collected during each irradiation. The 
results revealed that the phantom simulations and measurements follow the same behavior. The 2D 
time-resolved portal dosimetry showed to be able to detect more dose discrepancies caused by the 
tumor shifts than 2D time-integrated portal dosimetry. 
As main conclusion, 2D time-resolved portal dosimetry was superior in general to 2D and 3D time-
integrated portal dosimetry in detecting dose discrepancies caused by geometrical changes within 
the patients and the phantom. Time-resolved portal dosimetry is able to highlight discrepancies 
that are not shown when only the integrated portal dose images are compared. 
 
Keywords: radiotherapy – EPID – VMAT – portal dosimetry – geometrical changes   
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Resumo 
 
Em radioterapia externa com feixes de fotões é essencial que a distribuição de dose planeada seja 
entregue ao paciente com elevada precisão de modo a garantir a qualidade do tratamento. No 
entanto, existem certos tipos de erros que podem ocorrer durante as várias fracções de tratamento 
do paciente e prejudicar assim a qualidade do tratamento. Esses erros podem estar relacionados 
com o linac (acelerador linear) - posições incorrectas dos colimadores multi-folhas - ou com o 
paciente - erros de posicionamento do paciente ou alterações geométricas na anatomia do paciente. 
Os erros de posicionamento do paciente, como é o caso da translação ou rotação do paciente, 
podem fazer com que o feixe de radiação não atinja o tumor acabando por prejudicar o tecido 
saudável que se encontra à sua volta. No que diz respeito às alterações geométricas, as mais 
frequentes no decorrer do tratamento de radioterapia em pacientes com cancro no pulmão são o 
desvio do tumor, a regressão do tumor e a efusão pleural (excesso de fluido que se acumula na 
cavidade pleural). Estas alterações geométricas podem resultar numa discrepância entre a 
distribuição de dose planeada e a distribuição de dose que é realmente entregue ao paciente 
prejudicando assim a qualidade do tratamento. Deste modo, torna-se fundamental verificar a 
entrega da distribuição de dose quer antes quer durante o decorrer do tratamento do paciente de 
forma a detectar estes tipos de erros e garantir assim a qualidade do tratamento.  
Outro factor que também tem contribuído para uma maior exigência das práticas de verificação de 
dose durante o tratamento do paciente é o aparecimento de novas técnicas de radioterapia externa 
mais complexas que envolvem mais graus de liberdade, como é o caso da técnica de VMAT (terapia 
de arco volumétrico). O aumento da complexidade destas técnicas aumenta também a 
complexidade do tratamento e leva por isso a uma maior exigência na validação e controlo de 
qualidade (QA) do tratamento. 
Existem várias ferramentas de verificação de dose utilizadas em prática clínica para QA do 
tratamento e para detecção de discrepâncias de dose, como é o caso das câmaras de ionização, dos 
EPIDs (electronic portal imaging devices), dos filmes radiocrómicos, dos géis de polímeros ou outros 
detectores. O EPID tem sido o detector mais utilizado actualmente para a verificação de dose antes 
e durante o tratamento de radioterapia. Este detector obtém a distribuição de dose medida que 
depois é comparada com a distribuição de dose planeada (prevista). A análise gama é o método 
quantitativo mais utilizado para comparação de distribuições de dose. Este método utiliza em 
simultâneo dois critérios, a percentagem de diferença de dose (DD) e a distância de concordância 
(DTA), para o cálculo do índice gama pixel por pixel ou voxel por voxel. Ao aplicar um critério de 
aceitação (ex.: 3%, 3 mm), as discrepâncias entre as distribuições de dose de extensão geométrica e 
magnitude variável podem ser identificadas. 
Esta tese centra-se em dosimetria portal de transmissão em que o paciente se encontra entre o feixe 
de radiação e o EPID que mede a distribuição de dose entregue ao paciente. O aparecimento de 
novas técnicas de radiação mais complexas, como IMRT (radioterapia de intensidade modulada) e 
VMAT também tem levado ao desenvolvimento de novos métodos de verificação de dose com base 
em EPID. O método de 2D time-resolved portal dosimetry foi introduzido recentemente para a 
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técnica VMAT. Este método diferencia-se pelo facto de o EPID ler a distribuição de dose para cada 
segmento (duração compreendida entre dois pontos de controlo consecutivos) do VMAT em vez de 
ler apenas a distribuição de dose cumulativa (time-integrated portal dosimetry). 
O principal objectivo desta tese é a comparação do desempenho dos métodos 2D time-integrated, 
3D time-integrated e 2D time-resolved portal dosimetry na detecção de discrepâncias de dose em 
pacientes com cancro no pulmão causadas pela simulação de alterações geométricas na anatomia 
do paciente. 
Para tal foram simulados múltiplos desvios do tumor, múltiplas regressões do tumor e múltiplos 
níveis de efusão pleural (fluido que se acumula na cavidade pleural) em cada CT (Tomografia 
Computorizada) de planeamento de seis pacientes com cancro no pulmão que foram tratados com 
VMAT na MAASTRO Clinic. Também se procedeu ao cálculo de imagens de dose portal no CT de 
planeamento original e em cada CT manipulado (CT com a alteração geométrica já aplicada) 
recorrendo aos três métodos de dosimetria portal já referidos. De forma a comparar a dose 
planeada com a dose medida, foram feitas 2D time-integrated, 2D time resolved e 3D time-integrated 
gamma analyses para cada alteração geométrica simulada e para cada paciente utilizando cinco 
critérios gama diferentes.  
Posteriormente, foi investigado o desempenho de cada um destes métodos através da construção 
de curvas ROC (Receiver Operating Characteristic) e da determinação dos valores da área sob a 
curva (AUC). Como principais resultados, 3D time-integrated portal dosimetry foi o método que 
demonstrou o melhor desempenho (AUC = 0.85) na detecção de desvios do tumor e 2D time-
resolved portal dosimetry foi o método que revelou o melhor desempenho na detecção de 
regressões do tumor (AUC = 0.93) e de efusão pleural.  
Além disso também foi estudada a correlação entre a variação da métrica D95% do DVH (Dose 
Volume Histogram) calculado para cada paciente e as gamma fail rates obtidas para cada paciente e 
para cada tipo de alteração geométrica com cada método de dosimetria portal já referido. Esta 
correlação foi estudada tendo em consideração apenas um paciente, e tendo em consideração os 
seis pacientes como um grupo. Como resultado verificou-se que existe correlação a nível individual, 
mas não a nível colectivo. O facto de haver correlação a nível individual é bastante importante pois 
significa que no futuro será possível obter uma curva de regressão para cada simulação de um 
paciente e prever qual será a variação da métrica D95% a partir das gamma fail rates medidas e 
decidir assim quando adaptar o plano de tratamento do paciente em causa.  
Para além das simulações nos pacientes, também foi realizada uma experiência com um fantoma 
representativo do tórax humano (CIRS dynamic thorax phantom) com o intuito de replicar os 
desvios do tumor simulados nos pacientes. Foi feito um conjunto de simulações e medições 
experimentais seguindo o mesmo protocolo. No que diz respeito às medições experimentais, foi 
construído um mini-fantoma representativo do tumor (dois cilindros de PMMA - 
polymethylmethacrylate) com tecido pulmonar à volta (esponja) de forma a possibilitar a colocação 
de um filme radiocrómico entre os dois cilindros de PMMA. Nesta experiência foi feita uma 
irradiação com VMAT para cada desvio do tumor (mini-fantoma) aplicado no dynamic thorax 
phantom e a dose recebida no tumor foi medida em cada irradiação através de dosimetria com filme 
radiocrómico. Além disso, também foram adquiridas imagens portais do EPID durante cada 
irradiação. Os resultados deste estudo revelaram que as simulações e medições com o fantoma 
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seguem o mesmo comportamento. O método 2D time-resolved portal dosimetry demonstrou ter 
capacidade para detectar mais discrepâncias de dose causadas por desvios do tumor do que 2D 
time-integrated portal dosimetry. 
Como principal conclusão, 2D time-resolved portal dosimetry demonstrou ser o melhor método na 
generalidade para detectar discrepâncias de dose causadas por alterações geométricas da anatomia 
dos pacientes e no fantoma. Este novo método de dosimetria portal foi capaz de identificar 
discrepâncias de dose que não são reveladas quando se comparam apenas integrated portal dose 
images. 
 
Palavras-chave: radioterapia – alterações geométricas – VMAT – EPID – dosimetria portal  
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Front view of MAASTRO Clinic. 
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 Introduction 1
 
The development of more complex beam delivery techniques in external photon beam radiotherapy 
(EBRT), such as Intensity Modulated Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy 
(VMAT), has increased the need for accurate verification of the dose delivery during patient 
treatment to ensure treatment quality.  
Since VMAT uses many degrees of freedom during dose delivery, quality assurance (QA) is more 
difficult to perform for VMAT than for the conventional static radiation delivery techniques. Several 
verification devices specialized for arc trajectories have been used for performing VMAT QA, 
namely ArcCHECK (Sun Nuclear Corporation, Melbourne, FL), MatriXX (IBA, Schwarzenbruck, 
Germany) and Ocatvius (PTW, Freiburg, Germany) [1]. Apart from these devices, Electronic Portal 
Imaging Devices (EPIDs) have been used as an accurate tool for performing both pre-treatment and 
in-treatment dose delivery verification including time-integrated portal dosimetry and more 
recently, time-resolved portal dosimetry [2-4].  
Pre-treatment QA is able to detect dose delivery changes caused by problems related to the linac, 
such as errors in the beam delivery. However, dose delivery deviations caused by changes in patient 
anatomy can only be detected on the day of the treatment or during treatment. This project has 
focused on dose delivery errors due to geometrical changes in patient anatomy that can frequently 
and rapidly occur over the course of fractionated EBRT. Tumor regression, tumor shift and pleural 
effusion in the lungs are examples of such geometrical changes [5]. If not detected, these changes 
may cause the actually delivered dose to deviate from the planned dose, thereby damaging the 
surrounding healthy tissues instead of the tumor. 
In order to identify these dose delivery deviations in VMAT there are several EPID-based methods 
suitable for performing dose delivery verification. This project will focus on transit portal 
dosimetry in which EPIDs are used to obtain measured dose distributions behind the patient. 
Transit portal dosimetry is able to detect errors related to the beam delivery system itself and 
errors related to the patient [6]. Within transit portal dosimetry, 2D and 3D time-integrated portal 
dosimetry are currently employed in some radiotherapy centers [6-9]. Time-resolved portal 
dosimetry has been recently introduced for VMAT (Podesta et al. 2014 a) and has offered added 
value in assessing dynamic treatments. Instead of reading out the cumulative dose distribution to 
the EPID (time-integrated portal dosimetry), the dose distribution for each VMAT (time) segment is 
read out separately (time-resolved portal dosimetry) [2].   
The main goal of this project is to compare the performance of three different transit portal 
dosimetry methods in detecting dose delivery deviations caused by patient anatomical changes: 2D 
time-integrated portal dosimetry, 3D time-integrated portal dosimetry (3D in vivo dosimetry) and 
2D time-resolved portal dosimetry. 
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 Background 2
 
2.1  Cancer 
Cancer is characterized by the uncontrolled growth and spread of abnormal cells. If this spread is 
not controlled, it can result in serious illness and death. Cancer has become one of the greatest 
public health problems worldwide being one of the leading causes of morbidity and mortality. In 
2008 there were 3.2 million new cases of cancer and 1.7 million deaths from cancer in Europe [10]. 
In the United States the estimated number of new cancer cases projected for 2015 was 1,658,370 
and it was expected that about 589,430 Americans would die from cancer [11]. According to the 
World Health Organization (WHO), in twenty years from now the number of new cases of cancer 
will increase by 70% to more than 22 million cases [12]. 
 
2.1.1 Treatment options 
Nowadays there are three main modalities for treating cancer: surgery, chemotherapy and 
radiotherapy. Surgery is usually done when the tumor is accessible or when organ preservation is 
not an essential requirement. Chemotherapy uses systemic agents (drugs) to kill the abnormal cells 
which are dividing rapidly. In this way, in several cases chemotherapy is used together with surgery 
and radiation therapy. Radiation therapy (radiotherapy) uses ionizing radiation to destroy the 
cancer cells. The most common types of ionizing radiation used are electrons, photons, protons and 
heavy ions (e.g.: carbon). 
 
2.2 Radiotherapy 
Radiotherapy is one of the main modalities for treating cancer next to surgery and chemotherapy. 
In order to destroy the tumor cells inside the human body, ionizing radiation is used in 
radiotherapy. Ionizing radiation may cause deletions, substitutions and/or actual breaks in the DNA 
(deoxyribonucleic acid) chain. The double strand breaks are more difficult to repair and therefore 
responsible for cell death. The reproductive death of the tumor cell occurs when the radiation 
damage is not repaired (correctly), causing abnormalities in the chromosomes. 
The main goal of radiotherapy is to deliver a high dose to the tumor volume while minimizing the 
dose to the surrounding healthy tissue and nearby organs at risk (OAR) as much as possible. Since 
the surrounding normal tissues are also partially damaged by the radiation, a radiotherapy 
treatment is usually performed in a fractionated schedule, delivering the total dose in multiple 
treatments (fractions) to allow the normal tissues and nearby OAR to recover between fractions. In 
this way, an entire radiotherapy treatment typically consists of 30-40 fractions, 5 times per week, 
which takes approximately 6 or 7 weeks to deliver the total dose prescribed [13]. 
In radiotherapy, the radiation source can be located outside the patient (external beam 
radiotherapy), or within the tumor (brachytherapy). In brachytherapy a sealed radioactive source 
is introduced into or next to the area requiring treatment.  
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In EBRT the radiation is delivered from outside the patient by a linac. The radiation beams, mostly 
megavoltage x-rays (MV photon beams), electrons and protons, are focused on the tumor target and 
by using multiple beams in an optimum beam angle configuration is possible to limit the dose to the 
surrounding healthy tissues.  
 
2.2.1 External Mega Voltage Photon Beam Radiotherapy 
External Mega Voltage photon beam radiotherapy is the most common form of EBRT applied. This 
technique is implemented using linear accelerators that generate and accelerate electrons to 
energies ranging from 4 to 20 MeV (Figure 2.1). When these electrons collide with the tungsten 
target, high-energy MV X-rays or photons are produced. These high energy x-rays are shaped as 
they exit the linac to conform to the shape of the patient's tumor and the customized photon beam 
is directed to the patient's tumor. The beam may be shaped either by moulded blocks that are 
placed in the head of the linac (jaws) or by a multileaf collimator (MLC) that is incorporated into the 
head of the linac. The MLC typically consists of a series of 80 to 160 movable metallic leaves 
arranged in pairs. By changing their individual position, these leaves can block some fractions of the 
radiation beam thereby shaping the beam aperture according to the tumor shape [14]. 
 
 
Figure 2.1 – TrueBeam Varian High Energy linac equipped with (1) an electronic portal imaging device (EPID) which 
acquires MV images of the treatment beam and (2) a kilo Volt (kV) imaging system [15].  
 
(1) 
(2) (2) 
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2.2.2 Radiotherapy workflow 
The external photon beam radiotherapy process involves several steps until directing the dose to 
the proper locations of the patient. These steps can be divided into two different phases: 
preparation and treatment delivery (Figure 2.2). 
 
 
Figure 2.2 – Schematic overview of the external photon beam radiotherapy workflow. The feedback loop which involves 
treatment adaptation is also called adaptive radiotherapy. 
 
2.2.2.1 Preparation 
The preparation phase starts after the tumor diagnosis of the patient with the acquisition of the 
patient’s anatomical information. Generally the anatomical information is acquired with a CT 
scanner, typically one week prior to the start of the treatment. However, the anatomical 
information can also be acquired with other imaging modalities, such as Magnetic Resonance 
Imaging (MRI). In order to avoid the tumor growth between the CT-scan acquisition and the 
treatment start, the time between the acquisition of the CT and the first treatment should be as 
short as possible. The CT-scan is then transferred to the treatment planning system (TPS). This is 
one of the most important steps where the radiation oncologist delineates the target volumes on 
this initial CT, also called planning CT. The main target volumes to be considered in a treatment 
plan are the following: 1) Gross Tumor Volume (GTV) which is the gross palpable or visible extent 
and location of tumor; Clinical Target Volume (CTV) which is the GTV plus a certain margin to 
account for microscopic disease spread, and 3) Planning Target Volume (PTV) which is the CTV plus 
a certain margin to account for the effect of delivery uncertainties, such as patient set-up and intra-
treatment variations (e.g. organ motion) [16]. Besides the target volumes delineation, the OAR near 
the tumor site also have to be delineated in order to minimize the prescribed dose to them.   
Based on the anatomical information of the planning CT, the delineated structures and the dose 
prescription, the plan is generated and a 3D (planned) dose distribution is calculated. As a result, a 
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3D treatment plan is obtained which consist of dose information over a 3D matrix of points over the 
patient anatomy.  
The Dose Volume Histogram (DVH) summarizes the information contained in the 3D planned dose 
distribution and is the most common tool used for quantitative evaluation of treatment plans. A 
DVH is a histogram relating the radiation dose delivered to a tissue volume. Two types of DVH are 
possible: the differential DVH which shows the (relative) volume receiving a specified dose and the 
cumulative DVH which is the integral form and shows the (relative) volume receiving a specified 
dose or more. The most common one is the cumulative DVH. For a perfect treatment plan, the ideal 
cumulative DVH for a target volume would appear as a horizontal line at the top of the graph 
(100%), with a vertical drop at the prescribed dose indicating that 100% of the tumor volume 
receives the prescribed dose (Figure 2.3 (b)). In the case of a critical structure (OAR), the ideal 
cumulative DVH would appear as a horizontal line at the bottom of the graph and a vertical line at 0 
Gy, indicating that 100% of the critical structure receives 0 Gy (Figure 2.3 (b)). A drawback of the 
DVH methodology is the lack of spatial information [17].    
 
 
 
Figure 2.3 – Representation of cumulative DVHs. The ideal cumulative DVHs are represented on the right (b) for a target 
structure (prostate) and a critical structure (bladder) [17].  
 
The treatment plan is finalized by selecting the number of beams, the beam angles and 
corresponding weights, the beam energy and by defining the beam shapes. In this way, it is possible 
to achieve a homogeneous dose in the tumor and simultaneously spare the surrounding normal 
tissue structures by modulating the beam shape according to the tumor shape to fit the profile of 
the target. 
 
2.2.2.2 Treatment Delivery 
The need to reduce the dose to normal tissue and OAR while directing a high dose to the tumor 
volume has led to the development of newer modalities for treatment delivery: dynamic Intensity 
Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT). 
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2.2.2.2.1 IMRT 
In dynamic IMRT the fluence distributions are adapted to the treatment constraints of the patient 
and each radiation beam is modulated by continuously moving the leaves of the MLC which is a 
computer-controlled mechanical beam shaping device placed inside the linac head. For each beam 
direction, the optimised fluence distribution is achieved by sequential delivering several subfields 
with optimised shapes and weights. With these dynamically shaped fields, the dose distribution can 
be delivered more conformal to the tumor. 
 
2.2.2.2.2 VMAT 
More recently, there has been some interest in improving dynamic IMRT into a treatment modality 
where also the beam angle is continuously varied. This treatment modality is called VMAT and was 
first introduced in 2008 by Karl Otto [18]. VMAT can deliver highly conformal dose distributions by 
continuously and simultaneously varying gantry angle, field shape and dose rate during treatment 
[19]. The most important benefit of VMAT compared to the conventional IMRT techniques is the 
possibility of treating the whole target volume in a 360 degree-rotation therefore providing shorter 
treatment times, typically less than 2 minutes (Figure 2.4). 
The TPS (Eclipse, Varian Medical Systems) for VMAT uses control points (CPs) to optimise arc 
delivery treatment plans. The CPs consist of static configurations that the linac (MLC, gantry, etc.) 
should correspond and conform to during smaller arc sections in order to deliver the planned 
treatment. The term ‘CP’ is defined as the instantaneous configuration at a point in time while the 
term ‘segment’ is defined as the duration between two consecutive CPs [20]. In this way, N CPs 
correspond to N-1 segments. 
 
 
Figure 2.4  – Comparison between an IMRT (left) and a VMAT (right) plan. The VMAT plan was obtained with the 
RapidArc system commercialized by Varian Medical Systems. The VMAT plan shows a more conformed dose distribution 
[21].  
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2.2.2.3 Treatment verification 
 
2.2.2.3.1 Position verification 
The advanced developments of more complex delivery techniques like IMRT and VMAT have 
increased the need for accurate verification of patient positioning during treatment to ensure that 
the treatment is delivered as planned. As a result, modern linacs are equipped with two types of 
imaging detectors – EPID and kilo Voltage (kV) imaging system – to verify patient positioning 
during treatment (Figure 2.1). The EPID is used to image the MV treatment beam and therefore 
verify patient positioning, but it has been replaced over time by the kV-imaging system which 
acquires high quality online images and is able to reconstruct the 3D anatomical information of the 
patient into Cone Beam Computed Tomography (CBCT) images [22, 23]. 
 
2.2.2.3.2 Dose verification (portal dosimetry) 
Besides their application as imaging detectors, the EPIDs can also be used as planar dose detectors. 
The most common type of EPID available today is the amorphous-silicon (a-Si) EPID which consists 
of an X-ray converter that converts X-ray photons to visible light, an array of light detectors and an 
electronic acquisition system for receiving and processing the resulting digital image [6]. A more 
detailed characterization of this EPID will be presented in section 2.3.1. 
EPID measurements can be performed with minimum set‐up requirements and a 2D delivered dose 
conversion can be done immediately using the digital images acquired. Although an EPID image 
contains 2D and not 3D information, it is still possible to reconstruct the 3D dose distribution inside 
a patient or more recently, time-resolved or 4D dose distributions [6]. In this way, EPID dosimetry 
allows dose verification in: 1) a point; 2) a plane (2D); 3) 3D, and 4) 4D or time-resolved. Due to 
these capabilities, EPIDs can perform both pre-treatment (prior to the treatment) and in-treatment 
(during treatment) dose verification, also called portal dosimetry. 
To perform both pre-treatment and in-treatment portal dosimetry several steps are required. The 
first step is to acquire the planned dose and data from the TPS (e.g. planning CT) which will be then 
compared to the measured dose. Based on the planned dose and TPS data, point dose, planar dose 
(2D) or the 3D or 4D planned dose distributions are calculated with a prediction model. In a second 
step, when the treatment is being delivered the EPID images acquired need to be converted into 
portal dose images [2, 23]. Then, these 2D portal dose images can be used to reconstruct 3D or 4D 
dose distributions. Finally, it is necessary to do a quantitative comparison between the measured 
dose distribution and the planned (predicted) dose distribution using a dose comparison method. 
The most commonly used quantitative dose comparison method is the gamma evaluation [24]. 
 
2.2.2.3.2.1 Gamma evaluation method 
The gamma evaluation method is a tool by which the predicted and measured dose distributions 
can be compared in a quantitative manner in the dose and spatial domains [2, 24]. The method uses 
two criteria simultaneously, a geometrical distance to agreement (DTA) and a percentage dose 
difference (DD), to calculate the gamma value for each pixel/voxel in an image/volume. Each 
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reference point 𝑝𝑟  in the predicted dose distribution is compared to all evaluated points 𝑝𝑒  in the 
measured dose distribution. The points search in the measured distribution is limited to a search 
box ?̇? within which the points are evaluated, therefore allowing a shorter calculation time. The 
geometry of this search box can be a circle (2D gamma analysis) or a sphere (3D gamma analysis) 
having a radius that is defined as the region of interest [20, 25]. The gamma value |𝛾(𝑝𝑟)| is defined 
as the minimum distance between the reference point and the distribution of evaluated points, as 
described in the following equation. 
 
 |𝛾(𝑝𝑟)|=  min {√(
∆𝐷(𝑝𝑟,𝑝𝑒)
𝐷𝐷
)
2
+ (
∆𝑑(𝑝𝑟,𝑝𝑒)
𝐷𝑇𝐴
)
2
} ∀ {𝑝𝑒 ∈  ?̇?}       (2.1) 
 
Where ∆𝐷(𝑝𝑟,𝑝𝑒) and ∆𝑑(𝑝𝑟,𝑝𝑒) are the dose difference and geometrical distance between points 𝑝𝑟  
and 𝑝𝑒 , respectively. 𝐷𝐷 and 𝐷𝑇𝐴 represent the dose difference and distance to agreement selected 
for the gamma analysis, respectively. The dose difference and geometrical distance are normalized 
using acceptance criteria: percentage dose difference (𝐷𝐷) and distance to agreement (𝐷𝑇𝐴), 
respectively. The most common used acceptance (gamma) criterion is [3%, 3 mm] [26]. 
The calculated gamma value |𝛾| is then multiplied by the sign (+ or -) of the dose difference ∆𝐷. In 
this way, positive gamma values represent a dose increase (hotspot) in the measured dose 
distribution compared to the planned dose distribution whereas negative gamma values represent 
a dose decrease (cold spot) in the measured dose distribution compared to the planned dose 
distribution (Figure 2.5) [25]. 
As a final step, the acceptance criteria are applied. The pixels or voxels for which |𝛾|≤ 1 meet the 
acceptance criteria and are considered to pass the gamma analysis. The pixels or voxels for which 
|𝛾|≥ 1 do not meet the acceptance criteria and are considered to fail the gamma analysis [20]. 
 
 
Figure 2.5 – Example of a time-integrated gamma analysis. The hot spot shown in red represents an over-dosage whereas 
the cold spot shown in blue represents an under-dosage.                                                 
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The recent introduction of time-resolved portal dosimetry for VMAT (Podesta et al., 2014) led to 
the development of a time-resolved gamma analysis (Podesta et al., 2014) which allows a dose 
comparison in a time-dependent manner [2, 20].  
Despite time-resolved gamma analysis being similar to time-integrated gamma analysis, some 
parameters had to be added to the previous gamma function. The time dimension (∆𝑡) was 
introduced in the gamma function in addition to the already existing dose and spatial distance 
dimensions. A new acceptance criteria, time to agreement (𝑇𝑇𝐴), was also introduced in addition to 
the percentage dose difference and distance to agreement. Besides, the search box 𝜐 was extended 
by a time of interest.  
 
       |𝛾(𝑝𝑟 , 𝑡𝑟)|=  min {√(
∆𝐷(𝑝𝑟,𝑝𝑒)
𝐷𝐷
)
2
+ (
∆𝑑(𝑝𝑟,𝑝𝑒)
𝐷𝑇𝐴
)
2
(
∆𝑡(𝑝𝑟,𝑝𝑒)
𝑇𝑇𝐴
)
2
} ∀ {𝑝𝑒 ∈  ?̇?}        (2.2) 
 
The time-resolved gamma analysis produces multiple (time) frames - one frame for each VMAT 
segment while the time-integrated gamma analysis only produces one single frame for each beam. 
With time-resolved gamma analysis the predicted and measured portal dose images are compared 
for each VMAT segment [25]. 
 
2.2.2.4 Adaptive radiotherapy 
Currently, it is possible to detect patient anatomical changes during treatment delivery by 
monitoring treatments with kV imaging systems or with portal dosimetry. In order to figure out 
when the corresponding patient treatment plan needs to be adapted due to such anatomical 
changes, a new concept emerged in radiotherapy workflow: adaptive radiotherapy (ART). ART is a 
feedback loop that incorporates the information collected during the treatment course and enables 
a continuous adaptation of the patient treatment plan during the radiotherapy course to account for 
temporal changes in the anatomy of the patient [27, 28].   
Nowadays, ART is mainly performed based on image-guided radiotherapy (IGRT) by monitoring the 
kV CBCT data. However, these IGRT methods are qualitative and do not allow to quantify dose 
differences. To overcome this limitation, a few radiotherapy centers started taking into account the 
quantitative dose differences generated by portal dosimetry [29, 30]. This is also called dose-guided 
radiotherapy (DGRT). 
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2.3 State-of-the-art of EPID dosimetry 
Electronic portal imaging devices were originally developed for verification of patient positioning 
during treatment and to replace film that was previously used [31]. The images of the megavoltage 
treatment beam acquired by the EPID, also called portal images, have been used to identify errors 
in the patient set-up or errors of the radiation field placement prior or during field delivery. 
Shortly after their introduction in clinical practice as a tool for set-up verification measurements of 
the patient position, it was realized that EPID images also contained dose information [31]. Since 
then, several research groups started investigating the dosimetric characteristics of different types 
of EPIDs and different methods based on EPID dosimetry [6]. 
In most of the radiotherapy departments, EPIDs are already fixed to the linac due to its previous 
application as imaging detector for patient positioning verification. Consequently, it has become 
more advantageous for those departments also use EPID for dose verification without the need for 
additional hardware when compared to the other dosimetry devices.  
Several types of EPIDs have been developed and can be categorized according to their technical 
design. The first EPID being commercially available was the liquid-filled ionization chamber EPID 
(Li-Fi EPID), followed by the camera-based EPID (CC-based EPID) and, more recently, the 
amorphous-silicon EPID (a-Si EPID) which currently is the most used. [6]. 
  
2.3.1 a-Si EPID 
In 1995, Antonuk et al. described the amorphous-silicon EPID (a-Si EPID) for the first time [32].  
The device consists of an X-ray converter, a light detector and an electronic acquisition system for 
receiving and processing the resulting digital image [6, 32]. 
An example of an a-Si EPID commonly used nowadays is the aS1000 EPID from Varian Medical 
Systems (Figure 2.6). It is a flat panel imager composed by arrays of light sensitive amorphous-Si 
photodiodes arranged in a total 40 x 30 cm2 active detector area. Each frame is a scan of the 
detector elements and this EPID has a maximum frame rate of 9.574 fps. The aS1000 has in total 
1024 x 768 pixels; each pixel (picture element) consisting of a light sensitive photodiode and a thin 
film transistor to enable readout [34]. The picture elements register the amount of radiation that 
falls on them and convert that amount into the corresponding number of electrons. The electrons 
are then converted into electrical signals which are further processed by the imaging device or a 
computer resulting in the final digital image (portal image).   
 
 
Figure 2.6 – aSi 1000 EPID from Varian Medical Systems. 
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2.3.2 Methods based on EPID dosimetry 
In EPID dosimetry, also called portal dosimetry, two types of dose verification can be applied: pre-
treatment (performed prior to the treatment) and in-treatment (performed during treatment) 
dosimetry. 
In pre-treatment dose verification a comparison is done between the planned dose distribution 
(obtained from the TPS) and the measured dose distribution when the radiation beams are 
delivered outside patient treatment time, i.e. with open fields or a phantom. These measurements 
can be used e.g. to check the pre-treatment conditions and to determine the dose delivered to the 
EPID or to the phantom.  
In the case of in-treatment dosimetry a comparison is done between the planned dose distribution 
and the measured dose distribution when the radiation beams are delivered during patient 
treatment time. These measurements can be used to determine the dose delivered to the EPID or to 
the patient. 
There are different EPID-based dosimetry methods that can be categorized depending on whether 
or not radiation beams have been transmitted through an attenuating medium (a phantom or 
patient) between the source and the EPID (non-transit dosimetry and transit dosimetry, 
respectively) or whether the dose is reconstructed inside a phantom or a patient. There are also 
different arrangements for EPID dosimetry and different locations where the delivered dose 
distribution can be determined (at the EPID level or inside the patient/phantom), as represented at 
Figure 2.7 [6].  
 
 
Figure 2.7 – Representation of the different arrangements for EPID dosimetry, each one with the possibility to verify a 
dose distribution at the EPID level or inside the patient or phantom. Adapted from [6]. 
 
2.3.2.1 Transit portal dosimetry 
In order to ensure the quality of the radiotherapy treatment, it becomes vital to verify that the 
patient is receiving the correct dose during treatment. To this end, it has become important to 
determine the actually delivered dose from transit EPID images, based on the radiation beam 
passing through the patient, as described in Figure 2.7c.  In this way, the dose verification can be 
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performed either at the level of the EPID or by reconstructing the dose inside a digital 
representation of the patient. 
Transit portal dosimetry can be classified by point-dose verification, 2D portal dose prediction 
models, 3D dose reconstruction models and, more recently, 4D (time-resolved) dose reconstruction 
models.  
 
2.3.2.2 2D Transit portal dosimetry 
The 2D transit portal dose verification method consists of predicting the portal dose at the level of 
the EPID behind a patient or phantom. With this method, a 2D dose distribution can be measured 
behind a patient, thus allowing dosimetric treatment verification.  
Several research groups have proposed different 2D dose prediction models. These models 
calculate the planned portal dose at the position of the EPID, which can then be compared with the 
measured portal dose during treatment. If the predicted and measured portal dose distributions are 
equal, then the actual delivered dose to the patient is assumed to be the same as the planned dose. 
However, if there are discrepancies between the two dose distributions errors may have occurred 
during the patient treatment.  
Since the model developed by van Elmpt et al. (2005) is currently implemented at MAASTRO Clinic 
and will be used for the purpose of this project, it will be reviewed in this section [35]. This 2D 
portal dose prediction model describes the relation between three sets of data: two portal dose 
images, one with and a second without the patient between the beam source and the EPID, and the 
radiological thickness of the path crossed by the photons in the patient. In this way, the model is 
able to predict a 2D portal dose image behind a patient, based on a portal dose image without the 
patient in the beam in combination with the radiological thickness of the patient extracted from the 
planning CT scan. This model is therefore a tool that allows 2D verification of patient treatments by 
comparing predicted and measured portal dose images.  
  
2.3.2.3 3D (in vivo) portal dosimetry  
The 2D dose prediction models referred above allow the comparison between the planned and 
measured portal dose at the EPID level. However, if there are discrepancies between these two dose 
distributions it may be difficult to interpret the differences in terms of patient dose. In order to 
overcome this limitation, several methods have been developed to reconstruct the delivered dose 
distribution inside the patient from the EPID and then compare with the planned dose distribution 
obtained from the TPS [36-41]. In 3D portal dosimetry, the comparison between the two dose 
distributions is not done at the EPID level but at the patient level instead. One of those 
reconstruction models, which was used in this thesis, is the 3D dose reconstruction model 
developed by van Elmpt et al. (2006), which allows a full three-dimensional reconstruction of the 
dose actually delivered to the patient [36].   
This reconstruction model is based on measured EPID images without the patient placed in the 
beam and an independent dose calculation algorithm based on a Monte Carlo dose engine. The 
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model involves four steps until the final dose calculation (Figure 2.8). As a first step, a portal image 
is measured under the same conditions as the actual treatment and is converted into a portal dose 
image using a global calibration model for a-Si EPIDs (Nijsten S. et al.) [23]. The second step is to 
extract from this portal dose image the energy fluence exiting the linac. As a third step, a phase 
space distribution is sampled from the energy fluence. In the final step, the reconstructed phase 
space distribution is the starting point for the dose calculation. The 3D dose calculation is 
performed inside the patient or phantom geometry (planning CT or CBCT scan) based on the Monte 
Carlo XVMC code [42] 
 
 
Figure 2.8 - Schematic representation of the several steps involved in the model used for 3D in vivo dosimetry developed 
by van Elmpt et al. (2006). In a first step the 2D open-field portal dose images acquired by the EPID from all beam 
directions are converted to energy fluence. This energy fluence is then back-projected to level of the linac. Based on this 
new energy fluence distribution, a forward Monte Carlo 3D dose calculation is done inside the patient’s planning CT or 
CBCT scan. As a result, a reconstructed 3D dose distribution in the planning CT or CBCT scan is obtained. 
 
Several research groups have investigated the use of dose reconstruction models for performing 
verification of the dose delivered to the patient in three dimensions [6]. van Elmpt et al. (2009) 
presented and validated a model used for 3D in vivo dose verification based on information 
gathered during treatment, i.e. the patient anatomy using CBCT and the 2D transit EPID images. The 
dose information in these images was back-projected through the CBCT scan and used for Monte 
Carlo simulation of the dose distribution inside the CBCT scan, as represented in Figure 2.8 (van 
Elmpt et al., 2006). With this study it was possible to verify the dose delivered to the patient by 
combining in-room imaging with the transit dose measured during treatment [43].    
 
2.3.2.4 Time-integrated and time-resolved portal dosimetry for VMAT 
Due to the introduction of dynamic radiation delivery techniques where the fields are not static, like 
IMRT with dynamic MLC and VMAT, the concepts ‘2D transit time-integrated’ and ‘3D time-
integrated’ portal dosimetry appeared because in these dynamic techniques the images acquired by 
the EPID are time dependent. The EPID acquires a series of portal images during treatment delivery 
that are integrated over time at the end.    
Currently, to detect dose delivery changes in VMAT, 2D time-integrated or 3D time-integrated 
portal dosimetry are employed in some radiotherapy institutes. With these methods the doses in all 
VMAT segments over time are summed up. However, due to the integral nature of these methods, 
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there are also some dose deviations that will average out based on the arc trajectory resulting in 
minor or no indication of dose delivery deviation [5, 44]. 
Recently, time-resolved portal dosimetry was introduced for VMAT at MAASTRO Clinic [2, 20, 45]. 
With this novel method the comparison between the transit portal dose images acquired during 
treatment and the predicted transit portal dose images based on the planning CT of the patient is 
done separately for each VMAT segment during the arc trajectory. 
 
2.3.2.4.1 Clinical approaches 
As a consequence of the appearance of time-dependent radiation delivery techniques (dynamic 
IMRT and VMAT) in EBRT, several EPID-based methods for dose verification have been developed 
and improved in order to follow this technological development. In this section recent clinical 
approaches to time-integrated and time-resolved portal dosimetry for VMAT are reviewed. 
 
2.3.2.4.1.1 2D Time-integrated portal dosimetry 
Persoon et al. (2015) and Podesta et al. (2015) investigated if 2D time-integrated portal dosimetry 
for VMAT could detect dose differences caused by anatomical changes throughout the treatment 
course in a cohort of lung cancer patients [5]. These patients were treated with VMAT following 
daily CBCT-based images which were visually inspected for anatomical changes (e.g. tumor 
regression). When relevant geometrical differences were observed in the daily CBCT images 
compared to the original planning CT, it was decided to acquire a new planning CT. 2D time-
integrated portal dosimetry was performed to compare the planned dose distribution with the 
delivered dose distribution at the level of the EPID with the patient placed in the beam. The 
validated prediction model developed by van Elmpt et al. (2005) was used to simulate both the 
planned and delivered 2D portal dose images based on the patient geometries described by the 
planning CT and the new planning CT [35]. This study demonstrated that 2D time-integrated portal 
dosimetry could detect most geometrical changes caused by atelectasis (i.e. collapse or closure of 
parts of the lung). However, for other causes the method was not sensitive enough to identify the 
geometrical changes. This study concluded that 2D time-integrated portal dosimetry seems to hide 
certain dose delivery changes and therefore a time-resolved dose verification technique seems to 
be essential to verify VMAT dose distributions, which should be able to capture the dynamic and 
timed nature of VMAT. 
 
2.3.2.4.1.2 3D Time-integrated portal dosimetry (3D in vivo dosimetry) 
In order to investigate the exact cause of the dose discrepancies found with 2D transit portal 
dosimetry, it is mandatory to perform 3D portal dosimetry which allows a meaningful analysis of 
the delivered dose distribution in target volumes or OAR [6, 46]. 
Persoon et al. (2013) presented the first clinical results of adaptive radiotherapy based on 3D time-
integrated portal dosimetry for a group of five lung cancer patients treated with VMAT [29]. To 
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achieve that, they developed a method for 3D portal dose measurement (PDM), also called 3D time-
integrated portal dosimetry, combined with kV-CBCT imaging which can be seen in Figure 2.9. The 
2D EPID images were acquired during treatment and were automatically converted to 2D portal 
dose images [23]. These 2D portal dose images were then used as input for a 3D portal dose 
reconstruction algorithm to calculate the actually delivered 3D dose distribution of the day from the 
kV-CBCT image acquired prior to the treatment [47]. The dosimetric effect of the patient anatomical 
changes was quantified based on the 3D portal dose measurement. At the end a comparison was 
done between the measured and planned 3D portal dose distributions using the gamma evaluation 
and DVH analysis. The decision of re-planning the treatment plan of each patient was based on both 
quantitative dose analysis (gamma and DVH metrics analysis) and visual inspection of the kV-CBCT 
image.  
 
 
Figure 2.9 - Workflow of the 3D portal dose measurement acquisition and extraction of dose metrics from the DVH and 
gamma evaluations. On the left side a typical treatment planning process is depicted. On the right side the treatment 
process is depicted, the acquisition of the PDM. Adapted from [29]. 
 
This study showed that in four out of five patient cases, the treatment plan had to be adapted based 
on 3D time-integrated portal dosimetry and confirmed with a visual inspection of the kV-CBCT due 
to changes in atelectasis that induced shifts of the tumors and consequently a decrease of their dose 
coverage. It was demonstrated that 3D time-integrated portal dosimetry can play an important role 
in informed decision-making when adapting the treatment plan of a patient and is a promising 
method for detecting dose deviations over time for lung cancer patients. 
 
2.3.2.4.1.3 2D Time-resolved portal dosimetry  
Since 2D time-integrated portal dosimetry for VMAT seems to hide certain dose delivery changes 
caused by patient anatomical changes as shown by Persoon et al. (2015) and Podesta et al. (2015), a 
time-resolved dose verification method has become essential to verify VMAT dose distributions [5]. 
In order to overcome those limitations revealed by 2D time-integrated portal dosimetry, 2D time-
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resolved portal dosimetry for VMAT has been recently introduced at MAASTRO Clinic as a method 
for verifying the dosimetric information at the various time control points of the VMAT beam 
delivery. Instead of reading out the cumulative dose distribution to the EPID (time-integrated 
portal dosimetry), the dose distribution for each VMAT time segment is read out separately (time-
resolved portal dosimetry) [2, 25]. 
 
 
 
Figure 2.10 – Schematic overview of 2D time-resolved portal dosimetry (time-resolved transit planar dosimetry) for 
VMAT. The measured transit planar portal dose images per CP during treatment are compared to the predicted transit 
portal dose images per CP. A time-resolved gamma evaluation is used for dose comparison. The gamma evaluation results 
can be expressed by a gamma map or by a polar plot as function of the gantry angle where the red region represents an 
over-dosage and the blue region represents an under-dosage. Adapted from [45]. 
 
Persoon et al. (2015) and Podesta et al. (2015) presented a proof of principle in order to 
demonstrate that time-resolved transit planar dosimetry (2D time-resolved portal dosimetry) does 
not suffer from the same geometrical shortcomings of integrated methods and offers added value in 
detecting dose delivery changes caused by patient anatomical changes [45]. They studied a cohort 
of four patients, each showing a geometrical change during the course of the treatment: pleural 
effusion, rectal gas pockets and tumor regression. For time-integrated portal dosimetry, the portal 
doses in all CPs were summed over time. For time-resolved portal dosimetry the model used to 
convert the portal images into portal dose images was adapted such that a portal dose image per CP 
was generated (Figure 2.10). A comparison between the planned dose and the simulated delivered 
dose of VMAT beams was done per CP and calculated using the planning CT and the kV-CBCT of the 
day. The dose evaluation was performed with a static gamma evaluation for time-integrated portal 
dosimetry and with a time-resolved gamma evaluation for time-resolved portal dosimetry.  
This study demonstrated that for the four patient cases studied, time-resolved portal dosimetry 
was superior to time-integrated portal dosimetry. Time-resolved portal dosimetry was able to 
detect the geometrical changes of the patients while time-integrated portal dosimetry did not 
identify discrepancies in the dose delivery.  
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 Materials & Methods 3
 
3.1 Materials 
3.1.1 Clinical equipment and software  
At MAASTRO Clinic all patients are planned with Varian’s treatment planning system Eclipse v11 
using the Acuros dose algorithm. After treatment planning, patients are treated with VMAT which is 
delivered by a Varian TrueBeam linear accelerator. The linac can deliver photon beams of 6 and 10 
MV and is equipped with the a-Si EPID (the Varian aS1000) to acquire portal images and with a kV-
CBCT imager to acquire CBCT images during several treatment fractions. Portal images are 
acquired with Varian’s iTools, a software package to capture all individual image frames during the 
VMAT delivery.  
 
3.1.2 Research software 
For clinical research, the patient data are collected from the clinical database. Patient data consists 
of the treatment plans of the patients including the planning CT-scan acquired before treatment 
(typically one week before), the DICOM (Digital Imaging and Communication in Medicine) 
RTSTRUCT which contains information about the delineated structures and the DICOM RTPLAN 
that contains information related to the treatment itself (e.g. number of beams, beams energy and 
MLC positions). After patient data collection, these data can be loaded into the research software.  
In this thesis two in-house developed research software were used to perform portal dose 
calculations (TARDIS and Transformation GUI). Both of them are developed in MATLAB and are 
able to perform portal dose calculations for 2D and 3D time-integrated portal dosimetry and more 
recently, time-resolved (4D) portal dosimetry. These software are also able to generate DVH curves 
based on 3D dose distributions and to perform 2D, 3D and 4D gamma analyses (Figure 3.1).   
One of the software (Transformation GUI) also allows the simulation of different manipulations in 
the planning CT such as patient rotation, structure shifts and structure deformations. In this thesis 
this software was used to simulate geometrical changes within the patient by manipulating the 
patient’s planning CT. 
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Figure 3.1 – Snapshot of the TARDIS software with the DVH sharpness.  
 
 
3.2 Methods 
3.2.1 Patient simulations 
In order to investigate the impact of geometrical changes within a patient on the delivered dose 
distribution, a cohort of 6 Non-Small Cell Lung Cancer (NSCLC) patients from the clinical data base 
was used for analysis. All patients were treated at MAASTRO Clinic using VMAT, applying the dose 
in one or two-half arcs, using 6 or 10 MV photon beam quality delivered with a Varian True Beam 
Accelerator.  
During the course of a radiotherapy treatment of lung cancer patients, tumor shift, tumor 
regression and pleural effusion (fluid accumulated in the pleural cavity) are some of the most 
common geometrical changes that can occur within the patient between treatment fractions. 
Therefore, these three types of geometrical changes were simulated by manipulating the planning 
CT of each patient. Since a patient’s CT contains information about the photon attenuation (the 
linear attenuation coefficient can be obtained from the HU - Hounsfield Unit - values in each voxel), 
the dose calculations are performed on the CT image after converting the HU values into electron 
densities.  
 
3.2.1.1 Tumor shift 
Tumor shift was simulated by changing the absolute position of the tumor’s bitmask (GTV 
structure) and updating the corresponding HU values of the CT image. The voxels where the tumor 
used to be before being shifted are replaced by the HU values of the lung tissue (-750 HU which is 
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the standard HU value for lung tissue). The shifts were simulated along the Y axis because this was 
the one that induced more discrepancies in the resultant dose distributions. Figure 3.2 shows the 
directions of each axis and was used as reference for this thesis. 
 
 
Figure 3.2 – Snapshot of the Transformation GUI software. The representation of the X, Y and Z axis was used as 
reference for this thesis. 
 
Since the resolution of the CT image in the Y axis is 0.3 cm, multiple shifts of 0.3 cm were applied to 
the tumor to avoid image artifacts. The range of shifts applied goes from 0.3 cm until 3.9 cm in steps 
of 0.3 cm. The direction of the shifts applied along Y axis was chosen according to the tumor 
position inside the lung of each patient.  
Figure 3.3 shows an example of 5 multiple tumor shifts of 0.5 cm along the positive direction of Y 
axis in one of the patients case.  
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Figure 3.3 – Example of simulated tumor shifts of different magnitudes along the positive direction of Y axis. The blue 
contour represents the original PTV and the red contour represents the GTV (tumor structure). Top left: original CT 
(without tumor shift). Top center: 0.5 cm tumor shift. Top right: 1.0 cm tumor shift. Bottom left: 1.5 cm tumor shift. 
Bottom center: 2.0 cm tumor shift. Bottom right: 2.5 cm tumor shift. 
 
 
3.2.1.2 Tumor regression 
Tumor regression was simulated by applying a centroid-based deformation to the tumor structure. 
The magnitude of the regression was changed by multiplying the deformation vectors with a scaling 
factor. Before the deformation is applied to the tumor, the HU values of the voxels in the volume 
where the original tumor used to be were forced to -750 (standard HU value for lung tissue). 
Regressions between 10% and 90% were applied to the original tumor volume in steps of 10%. 
Figure 3.4 shows an example of simulated tumor regressions of different magnitudes. 
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Figure 3.4 – Example of simulated tumor regressions of different magnitudes. The blue contour represents the original 
PTV and the red contour represents the GTV (tumor structure). Top left: original CT (without tumor regression). Top 
center: 10% of tumor regression. Top right: 30% of tumor regression. Bottom left: 50% of tumor regression. Bottom 
center: 70% of tumor regression. Bottom right: 90% of tumor regression. 
 
3.2.1.3 Pleural effusion 
Pleural effusion is caused by fluid accumulation in the pleural cavity. Since the patient is in the 
supine position during treatment, gravity will cause the fluid to accumulate on the dorsal side of the 
pleural cavity. According to the MAASTRO clinical protocol, the extent of pleural effusion is the fluid 
level (in cm) in the sagittal slice (YZ plane) of the CT which contains the tumor centroid.  
Pleural effusion was simulated by forcing the HU values of the pleural effusion volume to be the HU 
value for water which is 0. In a first step, the absolute position of the tumor centroid is calculated 
and the sagittal slice which contains the tumor centroid is selected. In a second step, the absolute 
position of the first lung VOI voxel along the z axis is calculated (zmin). Finally, a pleural effusion 
bitmask that consists of all lung VOI voxels that have a z-coordinate such that z-zmin <= fluid level is 
created. The HU values of all CT voxels inside the pleural effusion bitmask were forced to 0 as 
referred above.  
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For patients where the tumor was positioned at the bottom of the lung, fluid levels were simulated 
between 0.1 cm and 1.0 cm in steps of 0.1 cm. Otherwise fluid levels were simulated between 0.5 
cm and 4.0 cm in steps of 0.5 cm.  
Figure 3.5 shows an example of simulated pleural effusion of different magnitudes inside the lung 
which contains the tumor. 
 
 
Figure 3.5 – Example of simulated pleural effusion of different magnitudes inside the left lung. The blue contour 
represents the GTV (tumor structure) and the red contour represents the right lung which contains the tumor. Top left: 
original CT (without pleural effusion). Top center: 1 cm of fluid level. Top right: 2 cm of fluid level. Bottom left: 3 cm of 
fluid level. Bottom right: 4 cm of fluid level. 
 
 
3.2.2 Dose evaluation 
After simulating the three types of geometrical changes of different magnitudes in the planning CT 
of each patient, portal dose images were simulated: one for the initial planning CT and one for each 
manipulated CT [35]. All simulations were performed using the initial unadapted treatment plan.   
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Figure 3.6 - Example of 2D and 3D dose distributions. Left: portal dose image at the EPID level. The shape of the dose 
distribution is caused by the position of the MLCs. Right: portal dose image reconstructed in 3D at the patient level. The 
couch is represented in the bottom (light green contour) and the body structure is represented in the center (XZ plane). 
The tumor (green contour) is inside the left lung (red contour). 
 
The comparison between the planned and simulated dose distributions (portal dose images) was 
performed at the patient level (3D time-integrated portal dosimetry) and at the EPID level (2D 
time-integrated and 2D time-resolved portal dosimetry). Figure 3.6 shows an example of a dose 
distribution simulated at the EPID level and at the patient level. The 3D dose distributions inside 
the patients were obtained using a Monte Carlo based three-dimensional dose reconstruction 
method derived from the portal dose images [36]. 
The portal dose images obtained with each portal dosimetry method for each transformation were 
compared with the original one (without transformation) using a global 2D gamma analysis in the 
case of 2D time-integrated and 2D time-resolved portal dosimetry and a global 3D gamma analysis 
in the case of 3D time-integrated portal dosimetry. In all gamma analyses five gamma criteria for 
global dose difference (%) and distance to agreement (mm) were employed: [1%, 1 mm], [1.5%, 1.5 
mm], [2%, 2 mm], [2.5%, 2.5 mm] and [3%, 3 mm]. Despite the [3%, 3 mm] gamma criterion being 
used at MAASTRO Clinic for clinical decision protocols and being the most commonly used for 
published studies (Low et al., 2013), there was interest in exploring other gamma criteria that could 
be more suitable than the [3%, 3 mm] [26]. In fact, published studies have indicated that this 
gamma criterion is not clinically relevant recommending stricter gamma criteria instead [48-50]. 
For the 3D time-integrated gamma analysis the results were expressed in terms of percentage of 
failing voxels and volume of failing voxels inside the GTV structure. For 2D time-integrated and 
time-resolved gamma analysis the results were expressed in terms of percentage of failing pixels 
inside the field mask, absolute area of failing pixels inside the field mask and absolute area of failing 
pixels inside the field mask per beam (2D time-integrated) and per segment (2D time-resolved). 
In the case of 3D time-integrated portal dosimetry, DVH curves were generated for each planning 
CT and for each manipulated CT based on the calculated 3D dose distributions and the D95% metric 
(dose to 95% of the volume) of the transformed GTV was extracted. The percentage of change of 
this metric inside each transformed GTV in comparison to the original GTV was determined 
according to the following formula: 
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                                         ∆D95% =  
D95%(Transformed GTV)−D95%(Original GTV)
D95%(Original GTV)
× 100 (%)                            (3.1) 
 
3.2.3 Correlation analysis between gamma results and differences in D95% metric 
To define decision support protocols for adaptive radiotherapy and prevent subjective decision-
making, portal dosimetry metrics should be linked to relevant changes in DVH metrics. Therefore, 
correlations between DVH metric (difference in D95% metric inside the transformed GTV) and 2D 
time-integrated, 2D time-resolved and 3D time-integrated portal dosimetry were investigated for 
all the five gamma criteria. 
The correlation analysis (Pearson’s R2) was performed in MATLAB for each patient separately and 
for the six patients as a group in order to investigate if there was a correlation not only within a 
patient but also between the 6 patients.  
 
3.2.4 Sensitivity and specificity of the gamma analysis  
The DVH analysis is the gold standard method used by physicians to look at dose discrepancies in 
clinical practice. However, it is known that the gamma analysis can detect dose discrepancies that 
sometimes are not detected by the DVH analysis [5].   
According to MAASTRO clinical practice, a difference between the planned and delivered dose is 
considered significant (gamma positive) when the [3%, 3mm] gamma fail rate exceeds the 
threshold of 10% in the in-field region of the 2D portal dose image for at least one beam. Regarding 
the DVH analysis, the delivered dose is considered to be deviating significantly from the planned 
dose (DVH positive) when one of the DVH metrics shows a difference higher than 4%.  
The same MAASTRO current action levels were used as reference to investigate the sensitivity and 
specificity of the gamma analysis methods. The difference of the D95% metric inside the transformed 
GTV calculated for each patient and each simulated geometrical change was used for DVH analysis. 
In the same way, the gamma fail rate inside the GTV calculated for each patient and each simulated 
geometrical change was used for gamma analysis.  
The DVH analysis was considered as the gold standard method and each gamma analysis method 
was considered as the diagnostic test. For all the five gamma criteria and each type of geometrical 
change, three ROC (Receiver Operating Characteristic) curves (Kumar and Indrayan, 2011) were 
generated: one for 2D time-integrated, one for 2D time-resolved and one for 3D time-integrated 
gamma analysis [51]. 
ROC curve is the plot that displays the trade-off between the sensitivity and (1-specificity) across a 
series of cut-off points. The validity of a diagnostic test compared with the gold standard is 
determined by the sensitivity and specificity. In order to quantify the performance of each gamma 
analysis method, the total area under the curve (AUC) was calculated for each ROC curve. The 
optimal threshold for each gamma analysis method and gamma criteria was obtained as the point 
on the ROC curve closest to the (0, 1) point [51].  
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3.2.5 Phantom simulations and measurements 
In order to replicate one of the geometrical changes simulated in the patients, a dynamic thorax 
phantom was used to mimic the simulation of tumor shifts inside the lung. A set of simulations and 
measurements of tumor shifts was performed with this phantom using the initial treatment plan. 
 
3.2.5.1 Phantom characteristics 
The CIRS Dynamic Thorax Phantom is a precision instrument for investigating the impact of tumor 
motion inside the lung (Figure 3.7) [52].  
The phantom body represents an average human thorax in shape, proportion and composition. A 
lung equivalent rod containing an air gap to insert a target and or various detectors is inserted into 
the lung equivalent lobe of the phantom. The phantom body is connected to a motion actuator box 
that induces 3D target motion through linear translation and rotation of the lung equivalent rod. 
Motion of the rod itself is radiographically invisible due to its matching density with the 
surrounding material. The target and its motion, given its density difference, can be resolved. The 
center of the target is positioned off central axis of the rod. 
 
 
Figure 3.7 – CIRS Dynamic Thorax Phantom. 
 
The phantom is composed by four different materials: plastic water (body), lung equivalent 
material (two lungs) and cortical and trabecular bone equivalent material (spine).  
A new insert representative of the tumor with lung tissue around was created in order to allow the 
placement of a Gafchromic EBT3 film piece within the tumor for dose verification. The PMMA 
(polymethylmethacrylate) cylinder insert, representing the tumor (approximately 120 HU), is 
placed inside a larger sponge cylinder (approximately -820 HU), representing the surrounding lung 
tissue (Figure 3.8). The insert can be separated in two in order to place the film and can be 
introduced into the air gap of the lung equivalent rod (Figure 3.9). The PMMA cylinder has a 2.5 cm 
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2.5 cm 
diameter and a 2.0 cm height in total.  The sponge is dry, viscous and made of 100% vegetable 
material.  
 
 
 
 
 
 
 
Figure 3.8 – Representation of the two parts of the insert composed by sponge and PMMA without the film piece (left) 
and with the film piece (right).  
 
 
 
Figure 3.9 – Representation of the lung equivalent rod of the phantom with the air gap on the top to introduce the whole 
insert.  
 
3.2.5.2 Phantom treatment plan 
A CT scan of the phantom with the new insert containing a film piece inside was acquired and a 
treatment plan was designed with ARIA research software (Varian Medical Systems) based on this 
planning CT. The phantom was planned to be irradiated using VMAT with a 6 MV photon beam at a 
Varian TrueBeam linear accelerator (Varian Medical Systems). The dose was planned to be 
delivered in two half-arcs as usual in many treatment plans of lung cancer patients. The dose per 
fraction was 2 Gy and the treatment consisted of 35 fractions in total. Figure 3.10 shows an axial 
slice of the CT of the phantom and figure 3.11 shows the treatment plan of the phantom.   
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Figure 3.10 - Axial slice of the CT image of the phantom with the new tumor model insert inside the left lung. 
 
 
 
 
Figure 3.11 – Representation of the treatment plan of the phantom in ARIA research software (Varian Medical Systems). 
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3.2.5.3 Phantom simulations 
In the same way as in the patient simulations, tumor shifts were simulated on the planning CT of 
the phantom. A range of shifts between 0.3 cm and 3.3 cm in steps of 0.3 cm was applied to the CTV 
structure along the negative direction of the Y axis. The reason to shift the CTV and not the GTV was 
to ensure that all tumor tissue including the edges was being shifted.  
After applying the tumor shifts, 3D portal dose images were simulated: one for the initial planning 
CT and one for each transformed CT. All simulations were performed using the initial unadapted 
treatment plan.   
A mask in the center of the tumor where the film piece is placed was created on the original CT 
image and on each transformed CT image. The mask consists of a circular area with a 0.5 cm radius 
in the XZ plane that covers 2 slices in Y axis. After interpolating each mask with the corresponding 
3D dose distribution, the mean dose inside the mask was determined.  
 
3.2.5.4 Phantom measurements 
In the same way as in the phantom simulations, the phantom was irradiated with the initial 
treatment plan. The same range of shifts was applied to the tumor along the negative direction of 
the Y axis using the CIRS Motion Control Software that enables to shift the lung equivalent rod 
which contains the tumor. For each tumor shift applied a new film piece was placed within the 
tumor insert, a new irradiation was performed and portal images were collected using the on-board 
EPID during irradiation (Figure 3.12). Afterwards, the portal images were converted to portal dose 
images [23]. 
 
 
Figure 3.12 – Setup of the phantom measurements. The phantom is positioned at the isocenter of the linac and the on-
board EPID is under the couch. 
 
The portal dose images from each tumor shift were then compared with the portal dose images 
obtained from the original tumor position using a global 2D gamma analysis that employs the five 
30 
 
gamma criteria already mentioned in section 3.2.2. Time-integrated and time-resolved gamma 
analyses were performed for each tumor shift. 
The film dose of each irradiation was determined using a red channel analysis and a calibration 
curve. Details regarding the film calibration and the measurement film analysis can be found in the 
appendix of this thesis. 
 
3.2.5.5 Comparison between phantom simulations and measurements 
A comparison between the phantom simulations and measurements was performed. For the 
simulation analysis, the mean dose inside the tumor mask where the film was placed was plotted as 
function of the tumor shifts. For the measurement analysis, the mean dose inside the central 
circular area of the measurement films was also plotted as function of the tumor shifts. 
 
3.2.6 Supplementary study 
In this study a cohort of 460 lung cancer patients described in a previous study (Persoon et al., 
2015) was used for analysis [5]. These patients were treated with VMAT following daily CBCT and 
were visually inspected for geometrical changes on a daily basis. Forty-six patients were subject to 
changes and had a re-CT with re-delineated contours and an adaptive treatment plan. The reasons 
for adaptation were: change in atelectasis (n = 18), tumor regression (n = 9), change in pleural 
effusion (n = 8) or other causes (n=11).  
Two portal dose images (one for the initial planning CT and other for the re-CT) were simulated for 
each patient [35]. In both simulations the patient was irradiated with the initial unadapted 
treatment plan. The portal dose images were compared using a global 2D gamma analysis and 
employing seven gamma criteria [1%, 1 mm], [2%, 2 mm], [3%, 2 mm], [3%, 3 mm], [4%, 4 mm], 
[5%, 3 mm] and [10%, 10 mm]. Both 2D time-integrated and 2D time-resolved gamma analyses 
were performed. The results were expressed in terms of fail rates, absolute fail area and absolute 
fail area per beam (2D time-integrated) and per segment (2D time-resolved).  
The main purpose of this study was to investigate the quantitative relationship between the gamma 
analysis results and the tumor volume as well as between the gamma analysis results and the 
survival of the patients. For the tumor volume analysis, 8 patients from the 46 patients cohort were 
excluded due to absence of GTV (n = 2), undefined contour sequence of the GTV (n = 2) or existence 
of more than one GTV (n = 4). In the case of survival analysis, 21 patients from the 46 patients 
cohort were excluded due to the fact that they were still alive on the day of patient data collection. 
The tumor volume was calculated for each patient based on the planning-CT and the DICOM 
RTSTRUCT by determining the sum of the voxels volume inside the GTV structure whereas the 
survival of each patient was calculated as the difference between the death date and the first 
treatment date of the patient. 
A correlation analysis (Pearson’s R2) was performed in MATLAB between the tumor volume and 
the gamma analysis results as well as between the days of survival and the gamma analysis results. 
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4 Results 
 
4.1 Patient simulations – a single patient 
Multiple DVH and gamma analyses were performed for each patient and each category of 
geometrical change (tumor shift, tumor regression and pleural effusion). Therefore, only the results 
relative to one patient and each geometrical change are shown in this section. 
For the 2D time-integrated and 2D time-resolved gamma analyses the gamma failure was calculated 
as fail rate (percentage of failing pixels), absolute fail area (cm2) and absolute fail area per beam 
(2D time-integrated) or absolute fail area per segment (2D time-resolved). In the case of 3D time-
integrated gamma analysis, the gamma failure was calculated as fail rate (percentage of failing 
voxels) and fail volume (volume of failing voxels). In this section only the results expressed as 
gamma fail rates are shown since this is the most common way of present the gamma failure in the 
literature. 
 
4.1.1 Tumor shift 
Based on the simulated 3D dose distributions, a DVH curve of the GTV was generated for each 
tumor shift applied. Figure 4.1 shows the DVH curves resultant from these simulations. The 
different line colors represent the different tumor shifts. It can be seen that the DVH curves are 
shifted to the left as a result of the tumor shift increase. The reason behind this is that when a shift 
is applied to the GTV, the GTV gets away from the highest dose region. By consequence, the volume 
receiving the planned dose decreases. 
The D95% metric inside the GTV was extracted from the previous DVH curves for each tumor shift. 
Figure 4.2 represents the percentage change of this metric as function of the tumor shift. There are 
negative values due to the fact that the differences of this metric were not calculated as absolute 
values. It can also be seen that for a tumor shift larger than 1.2 cm the difference in this metric 
starts decreasing. 
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Figure 4.1 – DVH curves for the original GTV and each shifted GTV. The red line represents the DVH of the original GTV 
and the other colors represent the DVH of each shifted GTV.  
 
 
Figure 4.2 – Difference in D95% metric of the GTV DVH as function of the GTV shift along the Y axis. 
 
2D time-integrated, 2D time-resolved and 3D time-integrated gamma analyses were performed for 
each tumor shift and gamma criterion. Figures 4.3, 4.4 and 4.5 show the gamma fail rates resultant 
from the tumor shift simulations obtained with these three gamma analysis methods and the five 
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gamma criteria. By comparing the three figures it can be seen that 2D time-integrated and 2D time-
resolved portal dosimetry are more able to detect smaller tumor shifts than 3D time-integrated 
portal dosimetry. For a [3%, 3 mm] gamma criterion the 3D time-integrated portal dosimetry only 
starts detecting dose discrepancies for a tumor shift equal or larger than 1.2 cm whereas 2D time-
integrated and 2D time-resolved portal dosimetry are capable of detecting a 0.6 cm tumor shift. 
 
 
Figure 4.3 – Gamma fail rates (percentage of failing pixels) for the tumor shift simulations obtained with 2D time-
integrated portal dosimetry. 
 
 
 
Figure 4.4 - Gamma fail rates (percentage of failing pixels) for the tumor shift simulations obtained with 2D time-
resolved portal dosimetry. 
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Figure 4.5 - Gamma fail rates (percentage of failing voxels) for the tumor shift simulations obtained with 3D time-
integrated portal dosimetry. 
 
 
4.1.2 Tumor regression 
For the tumor regression simulations DVH curves were generated based on the calculated 3D dose 
distributions. Figure 4.6 shows the DVH curves of the GTV as function of the tumor regression 
where the different line colors represent the different tumor regressions. The GTV DVH curves are 
shifted to the right as a result of the tumor regression increase. In fact when the GTV shrinks 
uniformly, the shrunken GTV gets more dose than the original one because now a smaller volume is 
receiving dose in the highest dose region (center of the radiation field). 
The D95% metric inside the shrunken GTV was extracted from each DVH curve. In figure 4.7 the 
difference in this metric is shown as function of the tumor regression. Despite the percentage 
change is small (the maximum is between 5% and 6%), it increases as the tumor regression 
increases. 
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Figure 4.6 – DVH curves for the original GTV and each transformed GTV. The different color lines represent different 
tumor regressions. The DVH for the original GTV is represented in red. 
 
 
Figure 4.7 - Difference in D95% metric of the GTV DVH as function of the GTV regression. 
 
As a result of the 2D time-integrated, 2D time-resolved and 3D time-integrated gamma analyses, the 
gamma fail rates were plotted as function of each new tumor volume resultant from the tumor 
regression and the gamma criterion as represented in figures 4.8, 4.9 and 4.10. The first new tumor 
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volume (68.7 cm3) corresponds to a tumor regression of 10% of the original tumor volume whereas 
the last one (6.0 cm3) corresponds to a tumor regression of 90%. The results reveal that 2D time-
integrated and 2D time-resolved portal dosimetry are able to detect smaller tumor regressions than 
3D time-integrated portal dosimetry. It can be seen that when employing a [3%, 3 mm] gamma 
criterion 3D time-integrated portal dosimetry can only detect a tumor regression larger than 50% 
(new tumor volume = 37.5 cm3) while 2D time-integrated and 2D time resolved portal dosimetry 
can detect a 30% tumor regression which corresponds to a new tumor volume of 51.5 cm3. 
 
 
Figure 4.8 – Gamma fail rates (percentage of failing pixels) obtained with 2D time-integrated portal dosimetry as 
function of the new tumor volume and the gamma criteria. 
 
 
Figure 4.9 - Gamma fail rates (percentage of failing pixels) obtained with 2D time-resolved portal dosimetry as function 
of the new tumor volume and the gamma criteria. 
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Figure 4.10 - Gamma fail rates (percentage of failing voxels) obtained with 3D time-integrated portal dosimetry as 
function of the new tumor volume and the gamma criteria. 
 
4.1.3 Pleural effusion 
DVH curves of the GTV were generated based on the 3D dose distributions for each level of pleural 
effusion in the lung which contains the tumor. Figure 4.11 shows the DVH curves according to each 
simulated level of pleural effusion where the different line colors represent the different levels of 
pleural effusion.  As a result of pleural effusion, the DVH curves are shifted to the left due to the 
presence of fluid inside the lung that attenuates the radiation dose and the volume receiving the 
planned dose decreases.  
In figure 4.12 a relationship can be seen between the difference of D95% metric extracted from the 
DVH curves and the different levels of pleural effusion. There are negative values due to the fact 
that the differences of this metric were not calculated as absolute values. The results reveal that 
pleural effusion causes a small change of the D95% metric (the maximum change is between -1.8 % 
and -2%). According to MAASTRO clinic current levels, a DVH is considered to be deviating 
significantly when a difference of the D95% metric is higher than 4%. In this way we can say that the 
pleural effusion simulations did not cause a significant change in the DVH of the GTV when obtained 
with 3D time-integrated portal dosimetry. 
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Figure 4.11 – DVH curves for the GTV after the simulation of different levels of pleural effusion in the lung which contains 
the tumor. The red line represents the original GTV without the presence of fluid volume in the lung.  
 
 
Figure 4.12 - Difference in D95% metric of the GTV DVH as function of the level of pleural effusion in the lung which 
contains the tumor. 
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The gamma fail rates resultant from 2D time-integrated, 2D time-resolved and 3D time-integrated 
gamma analyses are shown in figures 4.13, 4.14 and 4.15, respectively, as function of the fluid 
volume in the lung and the gamma criterion. The 3D time-integrated gamma analysis results 
produced lower gamma failures than 2D time-integrated and time-resolved especially for [2.5%, 2.5 
mm] and [3%, 3 mm] gamma criteria. When comparing the three figures, it can also be seen that 
time-resolved gamma analysis is able to detect a smaller fluid volume (201.2 cm3) than 2D and 3D 
time-integrated gamma analyses when using the largest gamma criteria ([2%, 2 mm], [2.5%, 2.5 
mm] and [3%, 3 mm]). 
 
Figure 4.13 - Gamma fail rates (percentage of failing pixels) obtained with 2D time-integrated portal dosimetry as 
function of the fluid volume in the lung which contains the tumor and the gamma criteria. 
 
Figure 4.14 - Gamma fail rates (percentage of failing pixels) obtained with 2D time-resolved portal dosimetry as function 
of the fluid volume in the lung which contains the tumor and the gamma criteria. 
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Figure 4.15 - Gamma fail rates (percentage of failing voxels) obtained with 3D time-integrated portal dosimetry as 
function of the fluid volume in the lung which contains the tumor and the gamma criteria. 
 
For all categories of geometrical changes it was shown that the [3%, 3 mm] gamma criterion was 
too lax to detect some of the dose discrepancies specially when performing 3D time-integrated 
portal dosimetry. By contrast the [1%, 1 mm] gamma criterion was too sensitive always detecting 
much more gamma failure than the other gamma criteria. Since it is very restricted it also detects 
noise and therefore more gamma failure. 
Pleural effusion was the geometrical change that produced more differences between 2D time-
integrated and 2D time-resolved gamma analyses. Table 4.1 shows both gamma analyses for each 
level of pleural effusion using the [3%, 3 mm] gamma criterion. The time-resolved gamma analyses 
are represented by their 104th (time) frames since these were one of the frames that show more 
differences when comparing with the time-integrated gamma analyses.  
Since the fluid volume has a higher electron density than the lung tissue, the radiation beam is more 
attenuated by the fluid volume (at the patient level) and the EPID gets lower dose as consequence. 
This under-dosage is represented in blue. It can be seen that the time-integrated gamma analysis 
only shows an under-dosage (blue region) for a fluid level equal or higher than 2.0 cm which 
corresponds to a fluid volume of 339.3 cm3. By contrast the time-resolved gamma analysis already 
shows an under-dosage for a fluid level of 0.5 cm (Table 4.1).  
Since time-resolved gamma analysis allows a dose comparison for each VMAT (time) segment along 
the arc trajectory, it is able to detect more dose discrepancies than 2D time-integrated gamma 
analysis which just compares the cumulative dose distribution.  
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Table 4.1 – 2D Time-integrated and 2D time-resolved gamma analyses (3%, 3 mm) for the simulated levels of pleural 
effusion in the lung which contains the tumor. 
Fluid level 2D Time-integrated 2D Time-resolved 
0.5 cm 
(140.5 cm3) 
  
1.0 cm 
(201.2 cm3) 
  
1.5 cm 
(267.6 cm3) 
  
2.0 cm 
(339.3 cm3) 
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2.5 cm 
(416.2 cm3) 
  
3.0 cm 
(496.0 cm3) 
  
3.5 cm 
(584.8 cm3) 
 
 
 
 
4.0 cm 
(677.2 cm3) 
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4.2 Correlation analysis  
To define decision support protocols for adaptive radiotherapy and prevent subjective decision-
making, gamma analysis metrics should be correlated to relevant changes in DVH metrics. Several 
research groups have been trying to find a correlation between gamma analysis and DVH metrics. 
Some published studies have found a correlation, but the majority could not find it [5, 53-56]. A 
correlation analysis between the difference in D95% metric and the gamma failure inside the GTV 
was performed in this study for the three categories of geometrical changes taking into account a 
single patient (the same patient as in section 4.1) and also the six patients as a group. The results 
expressed as fail rates for the [2%, 2 mm] gamma criterion are shown as example. 
 
4.2.1 Correlation analysis in a single patient 
In this section the correlation analysis results relative to the same patient whose results were 
shown in section 4.1 are presented. Figures 4.16, 4.17 and 4.18 show the correlation between the 
difference in D95% metric and the gamma fail rates resultant from the tumor shift, tumor regression 
and pleural effusion simulations, respectively. The gamma fail rates inside the GTV were obtained 
with 2D time-integrated (graph on the left), 2D time-resolved (graph in the middle) and 3D time-
integrated (graph on the right) gamma analyses. Each point of the graphs represents the result 
corresponding to one simulated geometrical change (eg. one tumor shift) and the straight line is the 
linear fit to the data.  
 
       
  
 
Figure 4.16 - Correlation between the difference in D95% and the gamma fail rate obtained with 2D time-integrated (left), 
2D time-resolved (middle) and 3D time-integrated (right) gamma analyses resultant from the tumor shifts simulations in 
one patient case. 
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There is a linear relationship between the difference in D95% metric and the gamma fail rates in a 
single patient especially for tumor regression and pleural effusion. For tumor shift, the data could 
be fitted to another function but the purpose was to use the same fit for all geometrical changes. 
The correlation coefficients do not vary considerably between the different gamma analysis 
methods. Even so, for tumor regression and pleural effusion 2D time-integrated and 2D time-
resolved gamma analyses showed a better correlation with the DVH metric than 3D time-integrated 
gamma analysis. The same was verified for the other gamma criteria apart from the [2%, 2 mm]. 
Figure 4.17 - Correlation between the difference in D95% and the gamma fail rate obtained with 2D time-integrated (left), 
2D time-resolved (middle) and 3D time-integrated (right) gamma analyses resultant from tumor regression simulations 
for one patient case. 
Figure 4.18 - Correlation between the difference in D95% and the gamma fail rate obtained with 2D time-integrated 
(left), 2D time-resolved (middle) and 3D time-integrated (right) gamma analyses resultant from pleural effusion 
simulations for one patient case. 
45 
 
4.2.2 Correlation analysis in six patients 
A correlation analysis was also performed for the three types of geometrical changes taking into 
account the results from the six patients as a group. Figures 4.19, 4.20 and 4.21 show the 
correlation between the difference in D95% metric and the gamma fail rates resultant from the tumor 
shift, tumor regression and pleural effusion simulations in the patients, respectively. The gamma 
fail rates inside the GTV were obtained with 2D time-integrated (graph on the left), 2D time-
resolved (graph in the center) and 3D time-integrated (graph on the right) gamma analyses. Each 
point of the graphs represents the result correspondent to one simulated geometrical change in one 
patient and the straight line represents the linear fit to the data. 
 
Figure 4.19 - Correlation between the difference in D95% and the gamma fail rate obtained with 2D time-integrated (left), 
2D time-resolved (middle) and 3D time-integrated (right) gamma analyses resultant from the tumor shifts simulations in 
six patients. 
Figure 4.20 - Correlation between the difference in D95% and the gamma fail rate obtained with 2D time-integrated (left), 
2D time-resolved (middle) and 3D time-integrated (right) gamma analyses resultant from the tumor shrinkage 
simulations in six patients. 
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Unlike the correlation analysis in a single patient, there is no correlation when involving the six 
patients as a group. Only pleural effusion revealed correlation coefficients larger than 0.5.  
 
4.3 Sensitivity and specificity of the gamma analysis 
The sensitivity and specificity of the different gamma analysis methods were determined for the 
tumor shift and tumor regression simulations based on ROC curves taking into account the results 
from all six patients. It was not possible to generate ROC curves for the pleural effusion simulations 
due to the absence of positive DVHs (DVHs where the difference in D95% metric was lower than 4%). 
The performance of the gamma analysis methods was quantified based on the AUC values. 
 
4.3.1 Tumor shift 
Figure 4.22 shows the ROC curves obtained for the tumor shift simulations for 2D time-integrated 
and 2D time-resolved gamma analyses whereas Figure 4.23 shows the ROC curves for 3D time-
integrated gamma analysis. The reference line indicates that the tested methods have 50% of 
probability in detecting the forced error (tumor shift). The curves were generated for all the five 
gamma criteria and the circle represented in each ROC curve indicates the optimal threshold point 
for that gamma analysis method (Table 4.2).  
Figure 4.21 - Correlation between the difference in D95% and the gamma fail rate obtained with 2D time-integrated (left), 
2D time-resolved (middle) and 3D time-integrated (right) gamma analyses resultant from the pleural effusion simulations 
in six patients. 
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Figure 4.22 – ROC curves resultant from the tumor shift simulations for 2D time-integrated and 2D time-resolved gamma 
analyses and for all the five gamma criteria used.  
 
Figure 4.23 - ROC curves resultant from the tumor shift simulations for 3D time-integrated gamma analysis and for all 
the five gamma criteria used.  
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In table 4.2 the optimal thresholds are shown for each gamma analysis method and gamma 
criterion. This table suggests that, for instance, for 2D time-integrated gamma analysis when 
employing a [3%, 3 mm] gamma criterion, a gamma threshold of 0.647% should be used as decision 
criterion to consider that the measured dose is deviating significantly from the planned dose 
distribution. This table also shows that laxer gamma criteria require lower optimal thresholds in 
order to be capable of flagging small dose discrepancies. 
 
Table 4.2- Optimal thresholds (%) obtained for 2D time-integrated, 2D time-resolved (% of failure inside the field mask) 
and 3D time-integrated (% of failure inside the GTV) gamma analyses corresponding to each gamma criterion for the 
tumor shift simulations. 
 
The AUC values were determined for each ROC curve. In Figure 4.24 the AUC values are shown for 
the ROC curves obtained for the tumor shift simulations for 2D time-integrated, 2D time-resolved 
and 3D time-integrated gamma analyses. Although the differences are small, the time-resolved 
gamma analysis shows a better performance than 2D time-integrated for almost all gamma criteria 
used. Even so, 3D time-integrated is superior to 2D time-resolved gamma analysis in detecting 
tumor shifts. 
 
 
Figure 4.24 – AUC values for the ROC curves generated from the tumor shift simulations for 2D time-integrated, 2D time-
resolved and 3D time-integrated gamma analyses.   
 Gamma criteria 
Gamma analysis  1%, 1 mm 1.5%, 1.5 mm 2%, 2 mm 2.5%, 2.5 mm 3%, 3 mm 
2D Time-integrated 10.5 7.07 3.58 1.50 0.647 
2D Time-resolved 13.5 11.3 9.10 5.99 3.73 
3D Time-integrated 52.1 32.0 19.2 11.8 8.68 
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4.3.2 Tumor regression 
As was the case of tumor shift simulations, ROC curves were obtained for the tumor regression 
simulations for 2D time-integrated and 2D time-resolved gamma analysis methods as shown in 
Figure 4.25 and for 3D time-integrated as shown in Figure 4.26. The curves were generated for all 
the five gamma criteria and the circle represented in each ROC curve indicates the optimal 
threshold point for that gamma analysis method (Table 4.3).  
 
 
Figure 4.25 - ROC curves resultant from the tumor regression simulations for 2D time-integrated and 2D time-resolved 
gamma analyses and for all the five gamma criteria used. 
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Figure 4.26 - ROC curves resultant from the tumor regression simulations for 3D time-integrated gamma analysis and for 
all the five gamma criteria used. 
 
Table 4.3 - Optimal thresholds (%) obtained for 2D time-integrated, 2D time-resolved (% of failure inside the field mask) 
and 3D time-integrated (% of failure inside the GTV) gamma analyses correspondent to each gamma criterion for the 
tumor regression simulations. 
 
As was the case of tumor shift simulations, the determined optimal thresholds were larger for 
2D time-resolved than for 2D time-integrated gamma analysis. Even so, the 3D time-integrated 
gamma analysis shows the largest thresholds. Since the [3%, 3 mm] is the most lax gamma criterion 
it requires lower gamma thresholds in order to flag the dose discrepancies as previously 
demonstrated by Table 4.2. 
The AUC values for the ROC curves obtained for the tumor regression simulations for the three 
gamma analysis methods are shown in Figure 4.27. The time-resolved gamma analysis is the 
method with the best performance for detecting tumor regression specially when using a [3%, 3 
mm] gamma criterion (AUC = 0.93). Comparing to the tumor shift simulations, 2D time-integrated 
 Gamma criteria 
Gamma analysis  1%, 1 mm 1.5%, 1.5 mm 2%, 2 mm 2.5%, 2.5 mm 3%, 3 mm 
2D Time-integrated 11.6 3.73 1.85 1.13 0.539 
2D Time-resolved 17.8 8.45 4.53 2.08 1.58 
3D Time-integrated 46.0 20.6 12.1 5.23 1.63 
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and 2D time-resolved gamma analyses showed a better performance for detecting tumor 
regressions than tumor shifts. By contrast, 3D time-integrated gamma analysis yielded a better 
performance for detecting tumor shifts than tumor regressions (AUC = 0.85 and AUC = 0.81, 
respectively). 
 
 
Figure 4.27 - AUC values for the ROC curves generated from the tumor regression simulations for 2D time-integrated, 2D 
time-resolved and 3D time-integrated gamma analyses.   
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4.4 Phantom simulations and measurements 
For the phantom simulations a 3D dose distribution was calculated for the original simulated tumor 
position and for each tumor shift using the same unadapted treatment plan. Figure 4.28 shows the 
overlap of each CT image and corresponding 3D dose distribution for the original tumor position 
(shift = 0) and for each tumor shift along the negative direction of Y axis. This sequence of images 
shows the tumor leaving the highest dose region according to the tumor shift increase. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Original Tumor shift = -0.3 cm Tumor shift = -0.6 cm 
Tumor shift = -0.9 cm Tumor shift = -1.2 cm Tumor shift = -1.5 cm 
Tumor shift = -1.8 cm Tumor shift = -2.1 cm Tumor shift = -2.4 cm 
Tumor shift = -2.7 cm Tumor shift = -3.0 cm Tumor shift = -3.3 cm 
Figure 4.28 - CT image and respective 3D dose distribution correspondent to the original tumor position (top left) and 
each tumor shift along the negative direction of Y axis. 
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The mean dose values inside the film region of interest were determined as function of the tumor 
shift applied along the negative direction of Y axis for both the phantom simulations and 
measurements, as can be seen in Figure 4.29. 
In both cases the mean dose starts decreasing sharply after a tumor shift of 1.5 cm. Although the 
curves show the same behavior, there are differences in the absolute dose values. These differences 
are due in part to errors during the measurements setup like sponge positioning errors. Even so, 
the results show that the measurements follow the same logic as the simulations, the mean dose 
starts decreasing after the same drop point (which corresponds to a tumor shift of 1.5 cm) and 
relates to the tumor shifts in the same way.  
 
 
 
Figure 4.29 – Mean dose inside the region of interest of the film for each tumor shift along the negative direction of Y 
axis. The blue and red curves represent the phantom simulations and measurements, respectively. 
 
4.4.1 Time-integrated and time-resolved gamma analyses 
Table 4.4 summarizes the results of the 2D time-integrated and 2D time-resolved gamma analyses 
obtained from the EPID images collected during the phantom irradiations. The gamma analyses 
were performed for the five gamma criteria already mentioned in section 3.2.2 but only the results 
for the [3%, 3 mm] gamma criterion are shown in this table. Each row of the table represents the 
time-integrated and time-resolved gamma analyses for each tumor shift applied along the Y axis. 
The time-resolved gamma analyses are represented by their 110th  time frame. The tumor is shifted 
towards the blue region. When the tumor is shifted, it occupies a region that was occupied by lung 
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tissue before. Since the HU values of the tumor tissue are higher than the HU values of the lung 
tissue, the dose in the new region where the shifted tumor is positioned is more attenuated at the 
level of the phantom resulting in lower dose (blue region) at the level of the EPID. The red region 
represents the region where the tumor used to be before shifting. This region is now occupied by 
lung tissue of the phantom which has lower HU values resulting in lower attenuation of the dose at 
the level of the phantom and therefore a higher dose (red region) at the level of the EPID. 
The time-resolved gamma analysis is able to detect a tumor shift of -0.3 cm. However, the time-
integrated gamma analysis almost does not reveal any dose discrepancy when this tumor shift is 
applied. The time-integrated gamma analysis is only able to detect tumor shifts larger or equal to     
-0.6 cm. For tumor shifts larger than -2.7 cm the blue region disappears due to the fact that the 
tumor is completely out of the radiation field.  
 
 
Table 4.4 – 2D Time-integrated and 2D time-resolved gamma analyses (3%, 3 mm) for each tumor shift inside the left 
lung of the phantom. 
Tumor shift 2D Time-integrated 2D Time-resolved 
-0.3 cm 
  
-0.6 cm 
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-0.9 cm 
  
-1.2 cm 
  
-1.5 cm 
  
-1.8 cm 
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-2.1 cm 
  
-2.4 cm 
  
-2.7 cm 
  
-3.0 cm 
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-3.3 cm 
  
 
 
4.5 Supplementary study 
 
4.5.1 Correlation between gamma failure and survival days  
A correlation analysis between the gamma failure and the survival days of the 25 patients was 
performed for all the seven gamma criteria referred in section 3.2.6. However, in this section only 
the results for the [4%, 4 mm] gamma criterion are presented since these were the ones which 
showed the stronger correlations. Each point of the graphs represents the result relative to each 
patient and the straight line represents the linear fit of the data. 
Figure 4.30 shows the correlation between the survival days and the gamma fail area per beam 
inside the radiation field mask obtained with 2D time-integrated gamma analysis (left side) and the 
correlation between the survival days and the gamma fail area per segment inside the radiation 
field mask obtained with 2D time-resolved gamma analysis (right side). 
 
 
Figure 4.30 - Correlation between the days of survival and the absolute gamma fail area per beam inside the field mask 
obtained with 2D time-integrated gamma analysis (left) and between the days of survival and the gamma fail area per 
segment inside the field mask obtained with 2D time-resolved gamma analysis (right) for [4%, 4 mm] gamma criterion. 
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Both gamma analyses show a very weak or non-existing correlation with the days of survival (R2 = 
0.019 for time-resolved gamma analysis and R2 = 0.035 for time-integrated gamma analysis). Even 
so, the time-resolved gamma analysis always shows more patients with gamma failure different 
from zero than the time-integrated gamma analysis. Despite the weak correlations, for both the 
cases the gamma failure decreases according to the increase of the survival days. This is an 
important finding that suggests that patients with lower gamma failure (less dose discrepancies) 
throughout the treatment fractions tend to survive more days after the first radiotherapy 
treatment. 
 
4.5.2 Correlation between gamma failure and tumor volume  
A correlation analysis between the gamma failure and the tumor volume of the 38 patients was 
performed for all 7 gamma criteria referred in section 3.2.6. However, in this section only the 
results for the [1%, 1 mm] gamma criterion are presented since these were the ones which showed 
the stronger correlations. Each point of the graphs represents the result relative to each patient and 
the straight line represents the linear fit of the data. 
Figure 4.31 shows the correlation between the tumor volume and the absolute gamma fail area per 
beam inside the radiation field mask obtained with 2D time-integrated gamma analysis (left) and 
the correlation between the tumor volume and the absolute gamma fail area per segment inside the 
radiation field mask obtained with 2D time-resolved gamma analysis (right) for a [1%, 1 mm] 
gamma criterion. As expected, the results reveal that the gamma failure increases with the tumor 
volume suggesting that patients with larger tumors get higher gamma failure areas over the course 
of the radiotherapy treatment. Time-resolved gamma analysis showed a stronger correlation with 
the tumor volume (R2 = 0.505) than time-integrated gamma analysis (R2 = 0.296). 
 
 
Figure 4.31 - Correlation between the tumor volume and the absolute gamma fail area per beam inside the radiation field 
mask obtained with 2D time-integrated gamma analysis (left) and between the days of survival and the gamma fail area 
per segment inside the radiation field mask obtained with 2D time-resolved gamma analysis (right) for [1%, 1 mm] 
gamma criterion. 
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5 Discussion 
 
The patient simulations showed that time-resolved portal dosimetry is able to detect dose 
discrepancies caused by tumor shifts, tumor regressions and pleural effusion more accurately and 
earlier during treatment than time-integrated portal dosimetry (Figure 4.26, Figure 4.27 and Table 
4.1). Moreover, the gamma analysis demonstrated to be a quantitative dose comparison method 
capable of identifying more deviations of the delivered dose from the planned dose than the DVH 
analysis which is the gold standard used by the physicians in clinical practice.   
The DVH analysis demonstrated to be more sensitive to tumor shifts than to tumor regressions and 
pleural effusion (the percentage change of the D95% metric inside the GTV was larger for the tumor 
shifts simulations than for the other geometrical changes). This could be explained by the fact that 
in the tumor shifts simulations the translation of the tumor relative to the central region of the 
radiation field is easier to detect when comparing, for instance, to a uniformly shrinkage of the 
tumor which remains in the central region of the field. 
The correlation analyses demonstrated that there is a quantitative relationship between gamma fail 
rates and difference in D95% metric for the 2D time-resolved, 2D and 3D time-integrated gamma fail 
rates when considering a single patient. This finding can allow establishing a relationship between 
D95% change and gamma fail rate for individual patients. It means that for every patient simulation 
we can get the regression curve, and use it to derive D95% changes from the measured gamma 
failure rates, and decide when to adapt the treatment. However, when taking into account the D95% 
metric and gamma fail rates results from all six patients, the correlation is very weak. This result 
suggests that the correlation is valid for a single patient geometry but when considering multiple 
patient geometries there is no correlation between the DVH metric and the gamma fail rates as have 
been reported by several published studies. Persoon et al. (2015) and Podesta et al. (2015) also did 
not find a correlation in 46 patients, each showing a geometrical change [5]. This fact suggests that 
studying a larger patient population will not lead to a correlation. 
The investigation of the sensitivity and specificity of the gamma analysis methods revealed that 
time-resolved gamma analysis yields a better performance than time-integrated gamma analysis 
for detecting tumor regression in the six patients studied. However, for capturing tumor shifts 3D 
time-integrated gamma analysis showed a better performance than 2D time-integrated and time-
resolved gamma analyses. The performance of gamma analysis in flagging pleural effusion could 
not be investigated due to the fact that there were no positive DVHs, i.e., the difference in D95% 
metric inside the GTV was never larger than 4% which is the MAASTRO clinical action level. This 
result suggests that DVH analysis is not suitable for detecting pleural effusion in lung cancer 
patients, at least not in the six patients studied here. It is also important to note that the results of 
this investigation depend on the clinical action level which is used as reference for considering a 
significant dose deviation of the delivered dose from the planned dose. 
In this work it was also demonstrated that the portal dosimetry methods show different 
performances according to the geometrical change simulated within the patient. It becomes 
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therefore essential to look individually for each category of geometrical change and define a specific 
gamma analysis threshold for each one of those problems.  
Moreover, it was also found that the [3%, 3 mm] gamma criterion was too lax to detect some of the 
dose discrepancies caused by the forced errors. Other studies have also shown that this gamma 
criterion is not suitable for gamma comparison in all cases and call into question its utility as an 
adequate metric in portal dosimetry [20, 48, 54]. In fact, despite being the most common gamma 
criterion it is unproven and arbitrary and should be changed according to the clinical needs [57]. 
Additional studies are necessary for choosing the optimal gamma criterion for both time-integrated 
and time resolved gamma analysis. 
The phantom measurements showed that in reality the geometrical change that we were testing in 
the simulations starts being significant at the same point as in the measurements. For both cases 
the dose to the tumor drops when a shift equal or larger than -1.5 cm in Y axis is applied to the 
tumor. Moreover, the EPID images acquired during the phantom measurements revealed that time-
resolved gamma analysis was able to detect more dose discrepancies caused by the tumor shifts 
and earlier than time-integrated gamma analysis. In fact, when applying a -0.3 cm shift to the tumor 
time-integrated analysis did not reveal any dose discrepancy while time-resolved gamma analysis 
showed some under-dosage and over-dosage regions resultant from the translation of the tumor. 
The supplementary study which involved a cohort of 38 patients allowed confirming that despite 
the weak correlation, there is a quantitative relationship between the gamma failure and the tumor 
volume as well as between the gamma failure and the survival days of the patients. These results 
suggest that a patient with a larger tumor has a trend to get a higher gamma area failure between 
treatment fractions. In the same way, there is a trend showing that a patient who got higher gamma 
failure (more dose errors) throughout the treatment course tends to survive less days after the first 
treatment day. This important finding suggests that high gamma failures over the treatment course 
of the patient can impair his recovery resulting in less days of survival. It becomes therefore 
essential to verify the dose delivery during treatment in order to avoid dose discrepancies. 
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6 Conclusion and Future Work 
 
This work demonstrated that time-resolved portal dosimetry is superior to time-integrated portal 
dosimetry in detecting anatomical changes in lung cancer patients caused by tumor shifts, tumor 
regressions and pleural effusion. The highly dynamic way of time-resolved portal dosimetry brings 
the advantage of measuring the dose during VMAT delivery from control point to control point 
thereby avoiding the geometrical shortcomings of the time-integrated portal dosimetry. Time-
resolved portal dosimetry was able to identify dose differences more accurately, with a higher 
sensitivity and earlier during treatment.  
The phantom measurements also confirmed the superiority of time-resolved portal dosimetry 
against 2D time-integrated portal dosimetry in flagging dose discrepancies caused by tumor shifts. 
Besides, it was shown that the measurements followed the same logic as the simulations: a shift of 
the tumor and replacing lung tissue by tumor tissue, results in similar effects in the simulations and 
the measurements. Thus, it was possible to mimic in reality the tumor shift simulations and 
demonstrate how they match.  
As main conclusion, this work is indicative that 2D time-resolved portal dosimetry shows 
promising results in catching dose discrepancies for VMAT treatments. Further research is still 
needed including a larger patient cohort but maintaining the different categories of geometrical 
changes with different magnitudes. New methods should also be investigated especially 3D time-
resolved portal dosimetry which allows a dose comparison per VMAT segment at the level of the 
patient. Other tumor sites than lung tumor should also be investigated with the same methodology. 
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Appendix 
 
A. Film calibration and measurement film analysis  
The film calibration was performed using ten pieces of GafChromic EBT3 films (International 
Specialty Product, NJ, US): one unirradiated and nine irradiated films. The films were irradiated at a 
Varian TrueBeam linear accelerator using a static 6 MV photon beam with a 10 cm x 10 cm field 
size. The films were irradiated with doses ranging from 0 Gy to 9 Gy in steps of 1 Gy.  
About the experimental setup, each film was placed between 15 cm of water-equivalent RW3 slab 
phantoms (PTW–Freiburg, Germany): 10 cm at the bottom to provide for backscatter and 5 cm at 
the top to provide build-up. The size of each slab phantom is 30 cm x 30 cm x 1 cm. The films were 
positioned at the isocenter of the linear accelerator (Figure A.1). 
 
 
Figure A.1 – Representation of 10 cm of water equivalent slab phantoms with a film piece positioned at the top at the 
isocenter of the linac. 
 
The films were placed between the solid water slab phantoms at the depth of 5 cm where 1 Gy 
equals to 100 MU. Since the calibration is performed at this depth and not at the maximum dose 
depth, the known dose is divided by PDD (Percentage Depth Dose)/100. According to MAASTRO 
clinical practice, the PDD for this measurement depth equals to 86% for a 6 MV photon beam with a 
10 cm x 10 cm field size. Since the ionization in the slab phantoms is slightly lower than in water, a 
correction factor is applied. This correction factor is the ratio between the ionization in the water 
and the ionization in the slab phantoms. For a 6 MV photon beam with a 10 cm x 10 cm field size 
and a 5 cm measuring depth this correction factor equals 1.009 (Figure A.2).  
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In order to deliver the known doses from 0 Gy until 9 Gy in steps of 1 Gy, the machine outputs in 
monitor units applied for each film irradiation were calculated based on the following formula: 
                                                               MU = hw/m  ⋅  
104⋅D
PDD
= 1.009 ⋅
104⋅D
86
 ,                                                    (A.1) 
where MU indicates the monitor units, hw/m represents the correction factor, D represents the dose 
and PDD is the percentage depth dose. 
 
 
Figure A.2 – The correction factor hw,m as a function of depth for the field size 10 cm x 10 cm [58].  
 
Table A.1 summarizes the machine outputs applied for each film irradiation and the respective dose 
values calculated according to the formula referred above. 
 
Table A.1 – Machine outputs applied for each film irradiation and corresponding dose values. 
Dose (Gy) 0 1 2 3 4 5 6 7 8 9 
Machine Output (MU) 0 118 235 353 471 558 706 823 941 1059 
 
After a period of six days post irradiation, the calibration and measurement films were scanned 
using an Epson Perfection V750 Pro flatbed scanner and Epson Scan software v3.83 (Seiko Epson 
Corporation, Nagano, Japan). Both calibration and measurement films were scanned separately in 
the center of the scanner with the same orientation. The scanned images were saved in RGB 
uncompressed tagged image file format (TIFF). These images were acquired at a resolution of 225 
dpi in 48 bit (16 bit per color channel) with all colour corrections turned off. The scanner was 
turned on half an hour before image acquisition and six preview scans were taken to warm up the 
scanner lamp. The films were always handled with gloves and stored in a black envelope when not 
being handled. 
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After the scanning process each film was analyzed using the red channel due to its high contrast. 
The pixel values (PV) of each image were converted to optical density (OD) using the following 
formula: 
OD =  −log10 (
PV
216
) , 
where OD represents the optical density, PV indicates the pixel value resulting from film 
digitization after irradiation and 16 indicates the number of bits per channel with which the images 
were acquired [59]. 
For the calibration analysis, a circular region of interest (0.5 cm radius) was defined in the central 
region of each calibration film piece. The average of the pixel values that fall into this radius was 
determined and converted to optical density using the formula referred above. Then the optical 
densities obtained for all calibration films were plotted as function of the known doses. To generate 
the calibration curve, the data points were fitted to the rational function OD(D): 
OD (D) =  a +  
b
D − c
 , 
where D represents the dose and a, b and c are the fit parameters [60]. The values that were 
determined for the fit parameters are shown in table A.2. Figure A.3 shows the calibration curve 
and the residual optical density.  
 
 
Figure A.3 – Film calibration curve (top) and residual optical density (bottom). 
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Table A.2 – Fit parameters of the calibration curve for red channel. 
 
 
For the measurement film analysis, a circular region of interest (0.5 cm radius) was also defined in 
the central region of each measurement film piece. The average of the pixel values that fall into this 
radius was determined and converted to optical density. Then, the optical density obtained for each 
measurement film was converted to dose based on the calibration curve function previously 
determined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fit Parameters 
a b c 
1.073 -6.16 -7.357 
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